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Abstract
Analysis and interpretation of complex lipidomic data using bioinformatic approaches
Lu Zhang
Dissertation advisor: Jeffrey H. Chuang
The field of lipidomics has rapidly progressed since its inception only a decade ago. Tech-
nological revolutions in mass spectrometry, chromatography, and computational biology
now enables high-throughput high-accuracy quantification of the cellular lipidome. One
significant improvement of these technologies is that lipids can now be identified and
quantified as individual molecular species. Lipidomics provides an additional layer of in-
formation to genomics and proteomics and opens a new opportunity for furthering our
understanding of cellular signaling networks and physiology, which have broad therapeutic
values.
As with other ′omics sciences, these new technologies are producing vast amounts of
lipidomic data, which require sophisticated statistical and computational approaches for
analysis and interpretation. However, computational tools for utilizing such data are sparse.
The complexity of lipid metabolic systems and the fact that lipid enzymes remain poorly
understood also present challenges to computational lipidomics. The focus of my disser-
tation has been the development of novel computational methods for systematic study of
lipid metabolism in cellular function and human diseases using lipidomic data.
In this dissertation, I first present a mathematical model describing cardiolipin molec-
ii
ular species distribution in steady state and its relationship with fatty acid chain composi-
tions. Knowledge of this relationship facilitates determination of isomeric species for com-
plex lipids, providing more detailed information beyond current limits of mass spectrom-
etry technology. I also correlate lipid species profiles with diseases and predict potential
therapeutics. Second, I present statistical studies of mechanisms influencing phosphatidyl-
choline and phosphatidylethanolamine molecular architectures, respectively. I describe a
statistical approach to examine dependence of sn1 and sn2 acyl chain regulatory mech-
anisms. Third, I describe a novel network inference approach and illustrate a dynamic
model of ethanolamine glycerophospholipid acyl chain remodeling. The model is the first
that accurately and robustly describes lipid species changes in pulse-chase experiments.
A key outcome is that the deacylation and reacylation rates of individual acyl chains can
be determined, and the resulting rates explain the well-known prevalence of sn1 saturated
chains and sn2 unsaturated chains. Lastly, I summarize and remark on future studies for
lipidomics.
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Chapter 1
Introduction
1.1 Lipidomics
Lipidomics is the systematic analysis of lipid molecular species and their interacting moi-
eties in a cell, organelle, globule, or whole organism [1]. The field of lipidomics emerged
from the technological revolutions in mass spectrometry instrumentation, particularly soft
ionization methods (matrix-assisted laser desorption/ionization, electrospray ionization and
tandem mass spectrometry) and chromatography, and was empowered by computational
biology in the late 1990s [2]. Lipidomics provides an additional layer of information to ge-
nomics and proteomics and opens a new area of research in biochemistry and cell biology,
Figure 1.1.
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Since its inception only a decade ago, it has rapidly progressed and successfully ad-
dressed questions in diverse biological systems. In 2001, the National Institute of General
Medicine (NIGMS) sponsored The Alliance for Cellular Signaling program to appreciate
the core function of lipid species in cellular signaling networks. Another NIGMS sponsored
project, Lipid Metabolites and Pathways Strategy (LIPID MAPS), has made substantial ef-
forts to catalog all of the lipids in the macrophage cell line RAW 264.7. Many lipid classes
and molecular species have been identified and quantified [3, 4]. As part of this process,
there has been a concerted effort to establish a standard lipid classification and nomencla-
ture into a comprehensive and integrated reference databases (http://www.lipidmaps.org/).
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Figure 1.1: Lipidomics - large-scale analysis of the cellular lipidome. (modified from
[1].) Novel approaches in chromatography and spectrometry now allow for systems-scale
quantification of lipids. Lipidomics provides an additional layer of information to genomics
and proteomics and opens a new area of research in biochemistry and cell biology.
3
1.2 Technological revolutions for lipid analysis
Mass spectrometry and chromatography methodologies for lipid analysis have undergone a
large change in the past decade, Figure 1.2. Since the 1950s, lipid extracts from biological
sources have been analyzed by chromatography and mass spectrometry. In the 1980s, thin
layer chromatography (TLC) was mostly used used to determine the content of entire lipid
classes. Gas chromatography-mass spectrometry (GC-MS) was used to determine total
fatty acid composition. In the late 1990s, tandem mass spectrometry (MS/MS) technique
enabled quantification of species with the same number of carbon atoms and double bonds
[5]. Ultimately, technologies progressed to the point where lipids can now be identified as
individual molecular species. High-throughput and high-resolution analysis of the complex
cellular lipidome is now possible [6, 7, 8, 9]. As these new technologies produce more
and more data, continued development of novel computational and statistical methods for
complex lipidomic studies using these new data will be required.
4
Figure 1.2: Revolution of lipid analytical technologies over the past decade. (modified
from [5].)
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The workflow of lipidomics begins with the extraction of lipids from a biological
source, e.g. tissues, cells, and subcellular organelles. Depending on the lipid compo-
nents being analyzed, different extraction and analytical separation strategies are used. For
glycerophospholipids, molecular species are profiled using a direct injection or shotgun
protocol. Subsequent absolute quantitation of lipid species is achieved by a detailed analy-
sis using LC-MS/MS or ESI-MS in combination with pertinent internal standards. Lastly,
pulse-chase protocols with labeled lipid precursors allow study of low abundance lipid
metabolites and flux analysis, Figure 1.3.
6
Figure 1.3: Schematic representation of lipidomic analysis. (Reprinted from [2].)
7
The focus of my dissertation has been the development of novel computational methods
for analyzing lipidomic data generated by Multi-Dimensional Mass Spectrometry-Based
Shotgun Lipidomics (MDMS-SL). In MDMS-SL, generally each lipid class or category is
first selectively ionized through intrasource separation followed by a class-specific diag-
nostic scan to generate an ion peak list of the molecular species in a lipid class of interest
for further acyl chain identification. This list is generated by matching the m/z values of
the detected ion peaks in the diagnostic scan with those of the candidate species in the
pre-established virtual database of the lipid class of interest. The list therefore contains in-
formation about the total number of carbon atoms and the total number of double bonds of
the acyl chains. To determine individual molecular species, the sum of the intensities of the
paired acyl carboxylates in their corresponding precursor ion scans or in product ion scans
in negative ion mode is used to assign the ratio between the acyl chain compositional iso-
mers. The presence of isobaric species (ions with the same mass, e.g., protonated 16:1-22:6
diacyl PE and 16:0-18:0 diacyl PC have different acyl composition but the same nominal
mass of 762), unlike the presence of isomeric species (which have the same chemical for-
mula but different structures, e.g., 18:0-18:2 diacyl PE and 18:1-18:1 diacyl PE), does not
affect acyl chain identification due to their differential total carbon number and total double
bond number which discriminate them [7, 10, 11]. The regioisomer ratio (e.g., 18:0-18:2
diacyl PE and 18:2-18:0 diacyl PE) is assessed by the ratio of the intensities of the paired
acyl carboxylates.
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1.3 Lipid metabolism
The cellular lipidome is comprised of diverse classes of sphingolipids, phospholipids,
glycerolipids, sterol lipids, and lipid metabolites (see major lipid classes and representa-
tive structures in Figure 1.4), whose molecular species coordinate biomembrane structure,
intra- and extra-cellular communication, metabolic efficiency, and signaling cascades that
are critical for cellular functionality in development and disease [12, 13]. Dysregulated
lipid metabolism can lead to severe pathophysiological consequences and have been as-
sociated with many diseases such as diabetes, cancer, as well as neurodegenerative and
infectious diseases [1]. Understanding of these distortions is a crucial problem, for cell and
developmental biology, potential diagnostics and treatments, and nutrition [5].
9
Figure 1.4: Major lipid classes and representatives. (modified from [14].)
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1.3.1 Fatty Acid
Fatty acid is a carboxylic acid with a long aliphatic chain, which varies by number of carbon
atoms and level of saturation Figure 1.4(a). The chain length usually ranges from from 4 to
28. Saturated fatty acids have no double bonds and unsaturated fatty acids have one or more
double bonds. Most naturally occurring unsaturated fatty acids are in cis configuration. The
"free fatty acids", i.e. not attached to other molecules, are mainly produced from hydrolysis
of triglycerides, or from phospholipids. They serve as a source of fuel by producing ATP
through beta oxidation, particularly for heart and skeletal muscle.
There are about twenty different needed fatty acids in human body. Figure 1.5 shows
the polyunsaturated fatty acid biosynthetic pathway in animals. Among them, linoleic acid
(18:2) and α-linolenic acid (18:3) are called "essential fatty acids" because human body
requires them but lack the desaturase enzymes required for their production.
11
Figure 1.5: The polyunsaturated fatty acid biosynthetic pathway in animals.
(Reprinted from [15]) Linoleic acid (18:2) and α-linolenic acid (18:3) must be provided
from dietary intake because human lack the enzymes to desaturate oleic acid.
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1.3.2 Glycerophospholipids
Glycerophospholipids comprise the vast majority of membrane lipid content. Each is com-
posed of a glycerol moiety, a polar head group linked via a phosphate to the sn3 position of
the glycerol moiety as well as an acyl chain esterified to the sn1 and the sn2 positions [16].
The hydrocarbon chain in the sn1-position can also be linked to the glycerol moiety via an
alkyl or alkenyl ether bond. Because of these variations as well as the variation of the length
and number of double bonds, glycerophospholipids comprise a great number of molecular
species. The molecular species composition is regulated by the complex homeostatic bal-
ance of biosynthesis at designated cellular sites, selective distribution or trafficking to new
sites, localized remodeling reactions (by transacylases or acyltransferases), and catabolism
[17, 18].
While the glycerophospholipids de novo biosynthesis pathway is relatively well un-
derstood, there is still much to know about the remodeling pathway (the Land′s cycle)
[19, 20, 21]. The Land′s cycle involves the deacylation/reacylation of existing cellular
phospholipids to create new molecular species. Phospholipases, such as Phospholipase A1
(PLA1) and Phospholipase A2 (PLA2), remove existing acyl chains to generate lysophos-
pholipids. Various transacylases or acyltransferases then reacylate the lysophospholipid
with a donor acyl chain, changing phospholipid architecture, which provides a platform for
numerous and diverse functional roles. Remodeling processes could in principle be com-
plex, as there is an abundance of acyltransferase, transacylase, and phospholipase isoforms,
13
which may be sn-1/sn-2 as well as acyl chain selective [21]. Characterization of lipid re-
modeling mechanisms is crucial to understanding the functional roles of lipids in biological
systems.
14
(a) PC (b) PE (c) CL
Figure 1.6: Representative structures of phosphatidylcholine (a), phos-
phatidylethanolamine (b) and cardiolipin (c).
15
1.3.3 Phosphatidylcholine
In the vast majority of tissues and membranes, the two most abundant glycerophospho-
lipids are phosphatidylcholine (PC) and phosphatidylethanolamine (PE), (see their repre-
sentative structures in Figure 1.7 (a) and (b)). PC and PE are mainly synthesized in ER.
In mammalian cells, it is known that phosphatidylcholine (PC) is synthesized predomi-
nantly via the CDP-choline pathway, and the PE N-methyltransferase (PEMT) pathway
accounts for 30% of synthesis in liver and a smaller fraction in other tissues [22, 23]. In
liver, PC species with mono- or di-unsaturated sn2 acyl groups such as 16:0-18:1/16:0-
18:2 are preferentially created in the CDP-choline pathway [22]. Similarly in heart, PC
species with mono-unsaturated acyl groups at their sn2 position are preferentially synthe-
sized, regardless of the chain type at the sn1 position (e.g., 18:0-18:1/18:1-18:1/16:0-18:1)
[24]. Meanwhile, the PEMT pathway shows no substrate specificity for PE, phosphatidyl-
N-monomethylethanolamine, or phosphatidyl-N,N-dimethylethanolamine [25], although
modest specificity for 16:0-22:6/18:0-22:6 has been reported [22].
1.3.4 Phosphatidylethanolamine
The biosynthesis of phosphatidylethanolamine (PE) involves the CDP-ethanolamine (Kennedy)
pathway and the decarboxylation of phosphatidylserine (PS) [26, 27]. These two alterna-
tive routes contribute differently to overall PE synthesis in different tissues. For example,
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in liver and heart, the CDP-ethanolamine pathway was reported to produce the majority of
PE, whereas in many other types of cells PS decarboxylase makes > 80% of PE [28, 29].
It has also been shown that these two pathways generate different PE molecular species
[30]. The CDP-ethanolamine pathway preferentially synthesizes PE species with mono- or
di-unsaturated fatty acids at sn2 position, (e.g., 16:0-18:2/18:1-18:2). The PS decarboxy-
lation pathway preferentially generates PE species with polyunsaturated fatty acids at sn2
position such as 18:0-20:4 [30]. After de novo synthesis, PC and PE acyl chain remodeling
involves transacylation or deacylation by PLA2 or PLA1, followed by reacylation mediated
by various acyltransferases [31, 32, 33].
1.3.5 Plasmalogen
Plasmalogens are a subclass of glycerophospholipids characterized by the presence of a
vinyl ether linkage at the sn1 position and an ester linkage at the sn2 position, Figure 1.7.
The most common head groups present in plasmalogen molecules are ethanolamine and
choline. They are widely distributed in animal kingdoms [34]. In mammals, the plasmalo-
gen content varies amongst different tissues. Nervous tissues, Inflammatory and immuno-
logical cells, kidney and testes contain relatively high levels of plasmenylethanolamine
whereas liver contains very little plasmalogens due to their secretion into plasma lipopro-
tein. In human heart, plasmenylcholine makes up a large portion of the choline phospho-
lipids [35].
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A number of functions have been proposed for plasmalogens, including serving as mod-
ulators of membrane dynamics, signaling molecules, antioxidants, and major storage pool
for polyunsaturated fatty acids [34]. Deficiencies of plasmalogens have been associated
with Alzheimer’s Disease [36, 37], Down syndrome [38], and cardiovascular disease [39].
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Figure 1.7: Basic structure of plasmalogens. Plasmalogens are a subclass of glyc-
erophospholipids characterized by the presence of a vinyl ether linkage at the sn1 position
and an ester linkage at the sn2 position. X represents a head group which is usually either
ethanolamine (PE) or choline (PC) in mammalian cells.
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1.3.6 Cardiolipin
Cardiolipin (CL) is unique among phospholipids because it contains four fatty acid (FA)
chains and is exclusively found in the inner mitochondrial membranes of eukaryotes [40,
41], (Figure 1.7 (c)). The only other place that CL can be identified is in the bacterial
membranes. Complex III, Complex IV and Complex V enzymes in the respiratory electron
transport chain of mitochondria have been shown to require associated CL molecules to
maintain their full functional roles [42]. CL molecular species vary dramatically during
development and among tissues. Abnormalities in these profiles have been associated with
changes in cellular bioenergetics and diseases, including Barth syndrome, diabetes, heart
failure, and cancer [41, 42, 43, 44, 45, 46]. The distribution and arrangement of molec-
ular species are thought to be achieved by acyl remodeling processes and have functional
significance. Because the potential variety of CL species is extremely large (O(N4) config-
urations are possible with N types of fatty acids), CL distributions and identified molecular
species have been difficult to analyze in numerous cases [45]. A systematic computational
approach is in great need for the analysis and understanding of CL regulation.
CL is de novo synthesized in mitochondria from the condensation of phosphatidylglyc-
erol (PG) and cytidine diphosphate-diacylglycerol (CDP-DAG). The four acyl chains of
this immature CL are largely comprised of shorter and saturated or mono/diunsaturated
acyl chains [42, 47, 48]. Immature CL species then undergo extensive remodeling. This
can be achieved by an acyl CoA dependent deacylation-reacylation cycle, or via transacy-
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lation using acyl chains from the sn-2 position of phosphatidylcholine (PC) and phos-
phatidylethanolamine (PE) [40]. A limited number of enzymes involved in CL remod-
eling, such as CoA:lysocardiolipin acyltransferase (ALCAT1), monolysocardiolipin acyl-
transferase (MLCL AT), tafazzin, and calcium-independent phospholipase A2 (iPLA2) are
known, though the specificities of these enzymes are not clear. There may also be many
other remodeling enzymes yet to be discovered [48, 49, 50, 51, 52, 53], and heterogeneity of
lipids within the membrane may affect their activity [54]. Technical advances in mass spec-
trometry technologies have generated tremendous amounts of quantitative lipid molecular
species data, providing valuable information for understanding these critical mechanisms.
1.4 Lipidomics in drug development
Lipid-based discoveries, offering an additional layer of information to proteomics and
genomics, can make contributions in many stages of drug development [1], Figure 1.8.
There are many successful drug classes, including cholesterol-lowering agents such as
statins (atorvastatin (Lipitor; Pfizer)) and cyclooxygenase inhibitors (for example, cele-
coxib (Celebrex; Pfizer), that are directed against lipid-metabolizing enzymes. Profiling
of lipid metabolites of paired samples, (e.g. healthy and diseased, control and dosed, wild
type and gene knockout) followed by differential analysis and multivariate statistics is par-
ticularly effective for initial identification of changes in lipid species between conditions,
and will help pinpoint enzymes and underlying metabolic pathways that are affected by a
21
perturbation of interest [55, 56, 57]. Once a target is identified, in vivo and in vitro studies
are carried out to screen for lead compounds that interfere with its function. Mass spec-
trometry is a valuable tool in this process that assays levels of known metabolites in tissue
or cell extracts in a highly selective and quantitative manner. Drug safety and toxicity could
be evaluated by monitoring the lipid composition of tissue and cell membranes [58]. Fur-
thermore, mechanistic modeling using lipidomic data could help to elucidate drug action
and diagnostics of diseases.
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Figure 1.8: Lipidomics in drug development. (modified from [1].) Lipid-metabolizing
enzymes are among successful drug targets. Lipidomics has already made contributions
and is expected to provide more valuable information in many stages of drug development,
from biomarker discoveries to clinical trials.
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1.5 Computational lipidomics
As with other ′omics sciences, lipidomics now requires more advanced computational
and statistical approaches to interpret datasets of complex distributions of lipid molecu-
lar species, which have broad and potent functional significance [59]. Thus, advances in
computational lipidomics can dramatically improve our understanding of the functions of
the cellular lipidome.
Early bioinformatics needs for lipidomics emphasized analytical issues such as mass
spectrometry data processing (peak integration, identification, and normalization), detec-
tion of low abundance lipid molecular species, quantification of lipid changes between two
or more conditions (e.g. in response to a perturbation), as well as dissecting lipid metabolic
signaling pathways at the class level [60, 61, 62, 63, 10, 64, 59, 65]. While emerging
technologies such as MDMS-SL are providing increasingly abundant high-resolution high-
accuracy lipidomic data [66, 3, 4, 67, 68], systems study of lipid metabolism and signaling
in cellular functions and human diseases will be facilitated. It is anticipated in the com-
ing years that sophisticated computational approaches will need to be developed for richer
understanding of how specific lipid species mediate complex biological processes and to
understand cross-talks between signaling pathways that were treated separately.
Quantification of phospholipid acyl behaviors is vital for understanding the regulation
of membrane physicochemical properties controlled by phospholipids. For example, it has
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been observed in Saccharomycescerevisiae that PC depletion is accompanied by dramatic
changes in species composition of PE via acyl chain remodeling, to maintain membrane
intrinsic curvature in an optimal range [69]. Knowledge of these behaviors will also im-
prove detection of molecular species lying just below current limits of lipidomic measure-
ment technology via cryptanalytic approach approaches that combine chemical detection
with computational simulation of acyl chain remodeling behaviors [10]. Lipid biochem-
istry will soon rely increasingly on this type of mechanistic strategy to further penetrate
and integrate the cellular lipidome. However, bioinformatic tools and models to interpret
MDMS-SL data are sparse [70, 71]. The further development of computational approaches
to mechanistically analyze lipidomic data would be extremely valuable.
1.6 Current Challenges
Modern lipidomics relies heavily on mass spectrometry for structural determination and
quantifications of lipids. However, there are several challenges for determining lipid struc-
ture information that cannot be addressed by mass spectrometry alone. Mass spectrometry
has provided evidence for the presence of isobaric and isomeric species that have the same
nominal mass and therefore overlap in the spectrum acquired on a low to moderately high
accuracy/resolution mass spectrometer for some lipid classes [72]. Isobaric species (ions
with the same mass) are normally from different lipid classes and therefore have different
head groups and thus different acyl composition. Isomeric species (which have the same
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chemical formula but different structures) are from the same lipid class and therefore have
identical acyl composition. Phospholipids often contain various isomeric species, including
acyl chain compositional isomers (e.g., 18:0-18:2 diacyl PE and 18:1-18:1 diacyl PE) and
regioisomers (e.g., 18:0-18:2 diacyl PE and 18:2-18:0 diacyl PE). Determination of isomer
concentration ratios is challenging. Although progress has been made toward determining
sn-1 and sn-2 acyl chain designations for diacyl- phospholipids using MDMS-SL analysis
[7], approaches to ascertain structural informations for more complex lipids, such as car-
diolipin, have yet to be developed. Chapter 2 discusses my research to interpret complex
lipid profiles using a mathematical modeling approach.
A large number of enzymes are involved in lipid metabolic pathways, including various
lipid synthases, phospholipases, lipid kinases, acyltransferases, transacylase, etc. Most of
the enzymes require specific recognition of their substrate species for catalysis [73]. For
example, mammalian fatty acid synthase (FAS), considered as a potential therapeutic tar-
get, preferentially generates palmitic acid (C16:0) and to a lesser extent produces C14:0
and C18:0 [74]. Highly specific interactions between lipid-lipid and lipid-protein are es-
sential for regulation of cell physiology [75, 5]. However, recognition of lipid is not well
understood. Thus novel analytical approaches are required that enable the identification
and characterization of lipid enzyme specificities at a systems level. In Chapter 3, I de-
scribe a statistical method for the comprehensive examination of phosphatidylcholine and
phosphatidylethanolamine enzyme specificities.
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Lipid molecular species are critical elements necessary for a comprehensive systems
analysis of cellular signaling networks. However, lipid species regulatory mechanisms
remain poorly understood. In Chapter 4, I discuss a novel network inference approach to
model the dynamic system of lipid acyl chain remodeling.
Collectively, these studies provide frameworks for systems-scale mechanistic discover-
ies using lipidomic technologies.
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Chapter 2
A mathematical model for the
determination of cardiolipin remodeling
mechanisms
2.1 Introduction
Phospholipids play a crucial role in biological systems. They act as key components in
membrane physiology, bioenergetics, cellular recognition, and signal transduction [76, 77,
78]. While the phospholipid de novo biosynthesis pathway (the Kennedy pathway) is rel-
atively well understood, there is still much to know about the remodeling pathway (the
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Lands cycle) [19, 20, 21]. The Lands cycle involves the deacylation/reacylation of ex-
isting cellular phospholipids to create new molecular species. Phospholipases, such as
Phospholipase A1 (PLA1) and Phospholipase A2 (PLA2), remove existing acyl chains at
sn1 and sn2 positions respectively to generate lysophospholipids. Various transacylases
or acyltransferases then reacylate the lysophospholipid with a donor acyl chain, changing
phospholipid architecture, which provides a platform for numerous and diverse functional
roles. Remodeling processes could in principle be complex, as there are an abundance of
acyltransferase, transacylase, and phospholipase isoforms, which may be sn-1/sn-2 as well
as acyl chain selective [21]. Characterization of lipid remodeling mechanisms is crucial to
understanding the functional roles of lipids in biological systems.
Advances in mass spectrometry now allow for the high-throughput analysis of the cellu-
lar lipidome, which is comprised of numerous lipid classes as well as signaling intermedi-
ates [79]. The multidimensional mass spectrometry based shotgun lipidomics (MDMS-SL)
approach is capable of simultaneously analyzing hundreds to thousands of lipid molecular
species, providing tremendous amounts of data that can be used to infer mechanisms of
lipid biosynthesis and remodeling in diseased and normal states [79]. However, bioinfor-
matic tools and models to interpret MDMS-SL data are sparse [70, 71]. The further de-
velopment of computational approaches to mechanistically analyze lipidomic data would
be extremely valuable, in particular for analysis of cardiolipin (CL, 1,3-diphosphatidyl-sn-
glycerol), a key polyglycerolphospholipid critically involved in energy metabolism, apop-
tosis, and membrane integrity [40].
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CL is unique among phospholipids because it contains four fatty acid (FA) chains and
is exclusively found in the inner mitochondrial membranes of eukaryotes [40, 41]. CL
molecular species vary dramatically during development and among tissues. Abnormalities
in these profiles have been associated with changes in cellular bioenergetics and diseases,
including Barth syndrome, diabetes, heart failure, and cancer [41, 42, 43, 44, 45, 46]. The
distribution and arrangement of molecular species are thought to be achieved by acyl re-
modeling processes and have functional significance. Because the potential variety of CL
species is extremely large (O(N4) configurations are possible with N types of fatty acids),
CL distributions and identified molecular species have been difficult to analyze in numer-
ous cases [45]. A systematic computational approach is in great need for the analysis and
understanding of CL regulation.
CL is de novo synthesized in the mitochondrial membrane from the condensation of
phosphatidylglycerol (PG) and cytidine diphosphate-diacylglycerol (CDP-DAG). The four
acyl chains of this immature CL are largely comprised of shorter and saturated or mono/diunsaturated
acyl chains [42, 47, 48]. Immature CL species then undergo continuous remodeling. This
can be achieved by an acyl CoA dependent deacylation-reacylation cycle, or via transacy-
lation using acyl chains from the sn-2 position of phosphatidylcholine (PC) and phos-
phatidylethanolamine (PE) [40] in mitochondria. A limited number of enzymes involved
in CL remodeling, such as CoA:lysocardiolipin acyltransferase (ALCAT1), monolysocar-
diolipin acyltransferase (MLCL AT), tafazzin, and calcium-independent phospholipase A2
(iPLA2) are known, though the specificities of these enzymes are not clear. There may
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also be many other remodeling enzymes yet to be discovered [48, 49, 50, 51, 52, 53], and
heterogeneity of lipids within the membrane may affect their activity [54].
Previously, the Chuang laboratory at Boston College and our colleagues observed that
the distribution of CL in the C57BL mouse (B6) brain could be qualitatively explained by
a simple steady state model for CL remodeling [42, 80]. The model assumed random acyl
chain incorporation into CL from a pool of PC (sn-2), PE (sn-2), and PG acyl chains, with
each of the four CL chain positions assumed to be independently and identically remod-
eled [81]. Although the model was able to closely fit CL profiles for the mouse B6 brain
mitochondria, the model has not been formally described and it is not known whether the
behavior is general for mitochondria in other tissues and diseased states.
As part of my effort to extend the Chuang laboratory’s bioinformatic tools for cardi-
olipin analysis, I developed a rigorous approach to systematically determine the CL remod-
eling mechanism in any sample at steady state. Using high throughput MDMS-SL data and
a maximum-likelihood approach, I analyze 18 types of samples, from mouse brain, heart,
lung, liver, tumor cells, and tumors grown in vitro. Improving on the assumptions of the
simple model above, I built a two-step analysis process to separately answer for any sam-
ple: whether the four chain positions of CL are independently and identically remodeled;
and how the acyl donors (PC, PE, PG, and acyl CoA) contribute to CL fatty acid composi-
tion. This study provides a fast and informative approach for testing hypotheses about CL
remodeling mechanisms.
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2.2 Method
2.3 Illustrative Example
2.3.1 Example Data
LetΩ be all possible fatty acid chain types in CL. Let Σ be all possible CL molecular species
givenΩ. In this example, we setΩ= {16 : 0,18 : 2} and Σ= {60 : 4,66 : 2,68 : 4,70 : 6,72 : 8}.
Assume we measured the following CL molecular species concentrations using MDMS-
SL:
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CL molecular species
(carbon: double bond)
All possible isomers
(sn-1, sn-1′, sn-2, sn-2′)
Replicate1
Concentration
(nmol/mg
protein)
Replicate2
Concentration
(nmol/mg
protein)
64:0 16:0-16:0-16:0-16:0 0.2 0.1
66:2 18:2-16:0-16:0-16:0
16:0-18:2-16:0-16:0
16:0-16:0-18:2-16:0
16:0-16:0-16:0-18:2
1.3 1.4
68:4 16:0-16:0-18:2-18:2
16:0-18:2-16:0-18:2
16:0-18:2-18:2-16:0
18:2-16:0-16:0-18:2
18:2-16:0-18:2-16:0
18:2-18:2-16:0-16:0
5.0 5.4
70:6 16:0-18:2-18:2-18:2
18:2-16:0-18:2-18:2
18:2-18:2-16:0-18:2
18:2-18:2-18:2-16:0
11.5 11.7
72:8 18:2-18:2-18:2-18:2 8.1 8.8
Total 26.1 27.4
Table 2.1: Illustrative example. Observed CL molecular species concentrations using
MDMS-SL measurement.
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Compute relative concentrations of CL molecular species and average among replicates
to obtain the observed probability distribution.
For example, µˆ72:8 = ( 8.126.1 +
8.8
27.4)/2 = 0.316. We can obtain the following probability
distribution:
CL molecular species Observed probability distribution
64:0 0.006
66:2 0.050
68:4 0.194
70:6 0.434
72:8 0.316
Table 2.2: Illustrative example. Probability distribution of illustrative CL molecular
species.
2.3.2 Independent and Identical Distribution Model predictions
To test the "independent and identical" hypothesis, let FA compositions of CL be PCL(18 :
2) = p and PCL(16 : 0) = 1− p. According to Equation 2.3 and 2.4, the IID probabilities
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of the CL molecular species are:
y64:0 = ∑
isomers
P(64 : 0 isomer) = (1− p)4
y66:2 = ∑
isomers
P(66 : 2 isomer) =
(
4
1
)
p(1− p)3
y68:4 = ∑
isomers
P(68 : 4 isomer) =
(
4
2
)
p2(1− p)2
y70:6 = ∑
isomers
P(70 : 6 isomer) =
(
4
3
)
p3(1− p)
y72:8 = ∑
isomers
P(72 : 8 isomer) = p4
The optimal parameter value can be computed by minimizing the error between the
predicted (yc:d) and observed (µˆc:d) probability distributions of CL molecular species,
Equation 2.5. Using matlab function lsqcurvefit, we obtain PˆCL(18 : 2) = pˆ = 0.7537 and
PˆCL(16 : 0) = 1− pˆ = 0.2463. The optimal predictions are the following:
CL molecular species Predicted probability distribution Observed probability distribution
64:0 0.0037 0.006
66:2 0.0450 0.050
68:4 0.2068 0.194
70:6 0.4218 0.434
72:8 0.3227 0.316
Table 2.3: Illustrative example. Predicted and observed probability distribution of illus-
trative CL molecular species.
To evaluate the goodness of fit, Pearson correlation coefficient is calculated between
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the predicted and observed distributions. We get r = 0.9985, suggesting the model could
probably describe the system correctly.
More rigorously, cross-validation is performed. Here we use leave-one-out cross-validation
as a demonstration. Parameter value pˆ is optimized from four training species and used to
predict the probability of the test species. Pearson correlation coefficient is calculated be-
tween the predicted and observed probability distributions as above. We get roriginal =
0.9969.
Training set Test species Predicted distribution Observed distribution
{66:2,68:4,70:6,72:8} 60:4 0.0037 0.006
{60:4,68:4,70:6,72:8} 66:2 0.0448 0.050
{60:4,66:2,70:6,72:8} 68:4 0.2118 0.194
{60:4,66:2,68:4,72:8} 70:6 0.4218 0.434
{60:4,66:2,68:4,70:6} 72:8 0.3351 0.316
Table 2.4: Illustrative example. Leave-one-out cross validation.
Four-fold cross-validation was used in real data analysis. Multiple runs were performed
using different random divisions of four fold subsets.
2.3.3 Permutation Test and Leave-one-out cross-validation
The observed probabilities of CL molecular species are shuffled, resulting in multiple ver-
sions of random data.
Leave-one-out cross-validation is implemented on each random dataset. Pearson corre-
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CL molecular species Random data 1 Random data 2 Random data 3
64:0 0.434 0.194 0.050
66:2 0.194 0.006 0.194
68:4 0.316 0.434 0.316
70:6 0.006 0.316 0.006
72:8 0.050 0.050 0.434
Table 2.5: Illustrative example. Randomly permuted data.
lation coefficient values are calculated and shown in the following table:
Random data 1 Random data 2 Random data 3
rrandom 0.2937 0.5218 -0.3246
Table 2.6: Illustrative example. Leave-one-out cross validation on randomly permuted
data.
The performances on random data are generally worse than on the original data. A one-
tail z-test is performed comparing roriginal and rrandom. P-value = 0.0285, which is below the
significant threshold 0.05, suggesting the model performance is not a random behavior. In
real data analysis, multiple runs of four-fold cross-validation results were considered thus
t-test was used instead of z-test. More random datasets are preferable for a valid statistical
test.
2.3.4 Proportional Incorporation model predictions
Molecular species concentrations and sn-1/sn-2 acyl chain designations are measured by
MDMS-SL for PC, PE, and PG. The FA compositions of PC sn-2, PE sn-2, and PG are
computed individually. For example, given the following PC concentrations:
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PC molecular species
(sn-1, sn-2)
Concentration
(nmol/mg protein)
16:0-16:0 17
16:0-18:1 10
18:1-18:1 24
18:1-18:2 4
16:0-20:4 19
18:2-22:6 26
Total 100
Table 2.7: Illustrative example. Observed PC species concentrations.
PPC(16 : 0) = 17/100 = 0.17
PPC(18 : 1) = (10+24)/100 = 0.34
· · ·
The probabilities of FA in CL can be computed using the IID model since they are not
readily available. Then we have the following lipid FA distribution table:
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Acyl chain type CL PC sn-2 PE sn-2 PG
16:0 0.20 0.17 0.07 0.32
18:1 0.48 0.34 0.13 0.51
18:2 0.04 0.04 0.01 0.01
20:4 0.09 0.19 0.27 0.07
22:6 0.19 0.26 0.52 0.09
Table 2.8: Illustrative example. Lipid FA distribution.
To test the proportional incorporation hypothesis, I use a set of weight parameters
(WPC,WPE ,WPG), subject to the constraints that WPC,WPE ,WPG > 0 and WPC +WPE +
WPG = 1, indicating the relative contributions from each acyl donor to the CL FA com-
positions, Equation 2.8. Parameter values are optimized using linear regression:

0.17 0.07 0.32
0.34 0.13 0.51
0.04 0.01 0.01
0.19 0.27 0.07
0.26 0.52 0.09

•

WPC
WPE
WPG
=

0.20
0.48
0.04
0.09
0.19

Using matlab function lsqlin, I obtain the optimal weights WˆPC = 0.454, WˆPE = 0 and
WˆPG = 0.546. The Pearson correlation coefficient between predicted and observed CL FA
distributions is roriginal = 0.97.
To evaluate the robustness of the model, FA compositions of each acyl donor lipid are
shuffled, resulting in random datasets. For example:
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Acyl chain type PC sn-2 PE sn-2 PG
16:0 0.26 0.13 0.07
18:1 0.19 0.07 0.01
18:2 0.34 0.52 0.09
20:4 0.04 0.27 0.32
22:6 0.17 0.01 0.51
Table 2.9: Illustrative example. Randomly shuffled lipid FA distribution.
A fit to the proportional incorporation model is performed on 10000 random datasets.
An empirical p-value is assigned as Pr(rrandom > roriginal). I get p-value = 0.028, which is
below the threshold 0.05, suggesting that the model performance is not likely random.
2.3.5 Sample Datasets
To compare CL remodeling between normal and pathological states, I analyzed 14 mouse
brain samples, described in [42]. The samples were C57BL/6J (B6) and VM/Dk (VM) in-
bred mice; an astrocytoma (CT-2A) and an ependymoblastoma (EPEN) that are chemically
induced from syngeneic B6 brain; two microgliomas (VM M2 and VM M3) and a stem cell
tumor (VM-NM1) that arose spontaneously from the syngeneic VM brain; and two brain
cell lines: astrocyte (non-tumorigenic) and BV2 (microglia). For each of these brain and
brain tumor samples, three biological replicates were performed. To compare CL remod-
eling across tissues, I studied brain, heart, lung, and liver from C57BL/6J(B6) wild-type
male mice (4 months of age), each with four biological replicates [10].
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2.3.6 MDMS-SL quantification of mitochondrial lipids
Extraction and quantification of the mitochondrial lipidome for these samples were previ-
ously described by Kiebish et al. [42, 10]. Briefly, tissue and tumor samples were harvested
from mature male mice or cell cultures, and mitochondria were isolated and purified. An
aliquot of purified mitochondria was transferred to a disposable culture borosilicate glass
tube. Internal standards were added based on the protein concentration (in nmol/mg mito-
chondrial protein). Lipids from each mitochondrial homogenate were extracted by a mod-
ified Bligh and Dyer procedure. Each lipid extract was reconstituted with mitochondrial
protein in chloroform/methanol. The lipids extracted were flushed with nitrogen, capped,
and stored at -20◦C. Each lipid solution was diluted prior to infusion and lipid analy-
sis. Lipid molecular species were identified and quantified by high resolution MDMS-SL,
which is described in detail in [7]. MDMS-SL allows for sn-1/sn-2 acyl chain determi-
nations for diacyl species because sn-1 and sn-2 carboxylate groups fragment at differing
rates in the mass spectrometry procedure. CL, PC, PE, PG, and acyl CoA (where available)
concentrations were normalized to probability distributions and averaged among replicates.
2.3.7 Independent and Identical Distribution Model
All of our models assume that data reflect steady state behavior [10]. Although remodeling
is dynamic, we are able to model steady-state behavior in the same way that chemical
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equilibria can be modeled without knowledge of individual reaction rates.
The IID model posits that four CL chain positions (sn-1, sn-1′, sn-2, sn-2′) are inde-
pendently and identically remodeled. Therefore each position is assumed to have the same
FA distribution. The concentrations of each FA chain are the parameters to be inferred for
each sample. I implemented a maximum-likelihood approach to infer these parameters.
Let Ω= {α1,α2, · · · ,αn} be all of the possible chain types in CL. The possible chain types
are assumed to be those observed within the acyl donors PC, PE, and PG (and acyl CoA
when available) in the sample.
Given the FA composition parameters in CL {PCL(α1),PCL(α2), · · · ,PCL(αn)}, the IID
probability of the CL isomer with acyl chain αi at position sn-1, α j at position sn-1′, αk at
position sn-2, and αh at position sn-2′ is defined by Equation 2.3:
P(αsn1i ,α
sn1′
j ,α
sn2
k ,α
sn2′
h ) = PCL(αi)PCL(α j)PCL(αk)PCL(αh) (2.3)
MDMS-SL measures the total concentration of CL molecular species with c carbons
and d double bonds in the acyl chains. The corresponding IID probability is summed from
the isomers matching c and d, as given by Equation 2.4:
yc:d = ∑
isomers
P(αsn1i ,α
sn1′
j ,α
sn2
k ,α
sn2′
h ) (2.4)
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The FA distribution can be found by a maximum likelihood approach which compares
yc:d with the experimentally derived species compositions µˆc:d . The likelihood of observ-
ing the data (for all CL species, S= 1,2, · · · ,N) given the model and parameters is assessed
by the error between the predicted and observed CL distributions, Equation 2.5:
E = ∑
species
(yS− µˆS)2 (2.5)
Minimizing the error function is equivalent to maximizing a likelihood function in
which deviations from the experimental value are distributed according to a Gaussian prob-
ability function. We assume the variance associated with each Gaussian to be identical,
which is reasonable since this is determined by the measurement uncertainty of the general
MDMS-SL procedure for CL. The optimal FA compositions are those that yield the mini-
mum error between the predicted and observed CL distributions, as described in Equation
2.6:
{
PˆCL(α1), PˆCL(α2), · · · , PˆCL(αn)
}
= arg min
P
E({PCL(α1),
PCL(α2), · · · ,PCL(αn)}|µˆ1, µˆ2, · · · , µˆN) (2.6)
I searched for optimal parameter values iteratively using the Matlab function lsqcurve-
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fit, with an initial condition of uniform probabilities (PCL(α1) =PCL(α2) = · · ·=PCL(αn) =
1
n), and under the constraints that PCL(α1),PCL(α2), · · · ,PCL(αn)> 0 and ∑ni=1 PCL(αi) = 1.
Least error and Pearson correlation between the optimal predicted and observed CL
probability distributions were used to evaluate the performance of the model. These gave
similar results. I set a threshold correlation coefficient of 0.7 to decide whether the model
explained the sample data.
2.3.8 Four-fold cross-validation
The measurable CL molecular species were randomly divided into four disjoint subsets of
equal size. Three subsets were used to train the model and the last was used for testing.
The training-predicting procedure was repeated four times, each time leaving out a different
subset. I then merged the predictions for the four test subsets and compared the resulting
predicted CL distribution to the observed data using Pearson correlation coefficient. For
the calculations of Table 2.10, the correlation was calculated in three separate runs, where
in each run the subsets of the CL data were divided by a different randomization.
2.3.9 Label permutation test
I performed a permutation test to assess the significance of the IID model’s performance.
For each sample, I generated a randomized version of the data by permuting the labels on
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CL concentrations. My null hypothesis was that there is no dependency between the fea-
tures (FA compositions) and the labeled values (CL species concentrations). I performed
four-fold cross validation on the randomized dataset and repeated this procedure three times
using different randomized labeling. A t-test was used to assess significance of the corre-
lation coefficient for the original data.
2.3.10 Independent and Differential Distribution Model
This model tests whether sn-1/sn-1′ and sn-2/sn-2′ positions of CL are differentially remod-
eled, maintaining the assumption that the four positions of CL are independent. It is similar
to the IID model, except having distinct FA compositions: P1CL(α1),P
1
CL(α2), · · · ,P1CL(αn)
for sn-1/sn-1′ positions and P2CL(α1),P
2
CL(α2), · · · ,P2CL(αn) for sn-2/sn-2′ positions. The
probability of the CL isomer with αi at position sn-1, α j at position sn-1′, αk at position
sn-2, and αh at position sn-2′ is defined by Equation 2.7:
P(αsn1i ,α
sn1′
j ,α
sn2
k ,α
sn2′
h ) = P
1
CL(αi)P
1
CL(α j)P
2
CL(αk)P
2
CL(αh) (2.7)
The parameter set
{
P1CL(α1),P
1
CL(α2), · · · ,P1CL(αn),P2CL(α1),P2CL(α2), · · · ,P2CL(αn)
}
is
optimized in the same manner as for the IID model. To compare the IDD and IID, I consider
the results of the four-fold cross-validation for each model. For a given sample, I perform
the four-fold cross validation for both IDD and IID in three runs each. Cross-validation
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requires a random data splitting, so for each run I split the data differently using a random
number generator. The observed correlation in the cross-validation is an indication of the
robustness of the model. To quantify IDD vs. IID I compare the distribution of correlation
scores (see Methods: four-fold cross-validation) for the three runs of the two models, using
a t-test.
2.3.11 Proportional Incorporation Model
The model assumes FAs from an acyl donor class are incorporated into CL at rates propor-
tional to their prevalence within the donor class. This is equivalent to assuming that there
are no chain-type specificities of remodeling enzymes, i.e. transacylases that transfer acyl
chains from PC and PE would have specificity for only the PC/PE head group and not the
length or saturation of the acyl chain. In this model, the acyl chain composition in CL is
a weighted sum of the acyl chain composition in each donor class (Equation 2.8). For PC
and PE, we allow only their sn-2 acyl chains to contribute to the acyl chain pool, consistent
with prior literature [82, 83, 84]. The weight parameters {WPC,WPE ,WPG} indicate their
relative contributions to CL, representing the overall effect of phospholipid concentration
and transacylase/phospholipase activities [85]. For example, if the affinity weights are WPC
= 0.5, WPE= 0.25, and WPG = 0.25, this means that of all the acyl chains making up the CL
species distribution, 50% originate from PC (sn-2) and 25% are derived from each of PE
(sn-2) and PG.
46
PCL(αi) =WPCPPC(αi)+WPEPPE(αi)+WPGPPG(αi) (2.8)
The optimal parameter values can be found by constrained linear regression. The
weight values are related to the observed CL concentrations via:

PPC(α1) PPE(α1) PPG(α1)
PPC(α2) PPE(α2) PPG(α2)
...
...
...
PPC(αn) PPE(αn) PPG(αn)

•

WPC
WPE
WPG
=

PˆCL(α1)
PˆCL(α2)
...
PˆCL(αn)

(2.9)
Here the acyl chain compositions in each of PC sn-2, PE sn-2, and PG (PPC,PPE ,PPG)
are experimentally determined. The acyl distribution within CL (PCL) is predicted using the
IID model, since experimental measurements for it were not readily available. I use Matlab
function lsqlin to infer optimal parameter values, which minimizes the error
∥∥∥∥C · x−d∥∥∥∥2,
with constraints WPC,WPE ,WPG > 0 and WPC +WPE +WPG = 1. The residual for a given
chain is defined to be that chain’s component of (d−C · x).
For B6 brain, heart, lung, and liver analysis, I additionally include acyl CoA as an acyl
donor, with weight parameter WAC (Equation 2.10):
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PCL(αi) =WPCPPC(αi)+WPEPPE(αi)+WPGPPG(αi)+WACPAC(αi) (2.10)
To assess the significance of model behavior, for each sample, I randomly permuted PC,
PE, and PG FA compositions (each column of C), and generated 10000 different random
datasets. An empirical p-value was assigned for the correlation coefficient of the true data
based on the distribution of coefficients in the random datasets.
Note that all of the models I have described are consistent with a dynamical system
at steady state. To clarify this relationship, I describe the corresponding dynamic system
for the Proportional Incorporation model, The IID and IDD models are analogous. The
dynamic model is similar to one previously described in [10]. Under a model in which all
four acyl chain positions behave equivalently, the dynamics of acyl chain type in CL are
given by the Equation 2.11:
d[α]CL
dt
= 4(1− γ)[KPC[PC][CL](PPC(α)−PCL(α))
+KPE [PC][CL](PPE(α)−PCL(α))]
+4γ[CL](PPG(α)−PCL(α)) (2.11)
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KPC and KPE are rate constants for the transfer of acyl chains from PC or PE sn-2 chains
into CL, respectively. γ is the degradation rate constant for CL. PPC(α) is the fraction of
PC chains that can be transferred into CL that are of type α (with similar definitions for
PPE(α) and PPG(α)). PCL(α) is the fraction of all CL chains that are of type α . Since I
have assumed that the total concentration of CL ([CL]) is in steady state, this obviates the
need for an explicit synthesis rate constant KPG.
The probability of chain type α in Cardiolipin is:
PCL(α) =
[α]CL
4[CL]
=
(1− γ)KPC[PC]PPC(α)+(1− γ)KPE [PE]PPE(α)+ γPPG(α)
(1− γ)KPC[PC]+ (1− γ)KPE [PE]+ γ (2.12)
This is equivalent to Equation 2.8, where
WPC =
(1− γ)KPC[PC]
(1− γ)KPC[PC]+ (1− γ)KPE [PE]+ γ (2.13a)
WPE =
(1− γ)KPE [PE]
(1− γ)KPC[PC]+ (1− γ)KPE [PE]+ γ (2.13b)
WPG =
γ
(1− γ)KPC[PC]+ (1− γ)KPE [PE]+ γ (2.13c)
In the following section, I will illustrate the main idea of this method by a simple
49
example.
2.4 Results
2.4.1 Characterization of cardiolipin molecular species distributions
across samples
The lipidomic data is derived from highly purified mitochondria as described by Kiebish
et al. [42, 10]. Fourteen mouse brain samples were analyzed, including two normal strains
C57BL/6J (B6) and VM/Dk (VM, which has a 210-fold increase in spontaneous brain
tumor formation) [47]; B6 derived astrocytoma tumor (CT-2A) and ependymoblastoma tu-
mor (EPEN); VM derived stem cell tumor VM-NM1; and two microgliomas (VM M2 and
VM M3). Tumors were grown in vivo and as cultured cells in vitro [86, 87]. Two addi-
tional cell lines, astrocyte (non-tumorigenic) and BV2 (microglia), were used as controls.
I also analyzed B6 mouse tissues from heart, lung, and liver. For each sample, the mass
content and distribution of lipid molecular species (CL, PC, PE, PG) were quantified, with
acyl CoA additionally measured for the B6 brain, heart, lung, and liver samples. We de-
termine by MS the number of carbons and number of double bonds in the entire molecule
of cardiolipin. The sn-1 and sn-2 acyl chain designations of diacyl phospholipids (PC, PE,
and PG) were determined by MDMS-SL analysis [7]. In general, CL profiles are consis-
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tent in replicates of a sample, but are diverse among different samples and tissues. Figure
2.1 shows a comparison of the samples B6 mouse brain mitochondria, EPEN brain tumor
mitochondria, and B6 mouse heart mitochondria. The data suggest wide variations in lipid
synthesis and remodeling processes across samples.
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Figure 2.1: CL profiles are similar within biological replicates, but vary among sam-
ples/tissues.
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Figure 2.1: CL profiles are similar within biological replicates, but vary among sam-
ples/tissues. Cardiolipin species are labeled along the x-axis by total number of carbons
and double bonds in the four acyl chains of the entire molecule, and the y-axis shows
MDMS-SL measured concentrations. C57BL/6J (B6) mouse brain mitochondria, EPEN
mouse brain tumor mitochondria, and B6 mouse heart mitochondria are shown as exam-
ples. Error bars represent standard deviation of three replicates.
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2.4.2 Independent and Identical Distribution Model to describe CL
profiles
The MDMS-SL procedure is capable of detecting more than 100 mass peaks of CL, each
containing tens to hundreds of possible CL isomers. Given the potential complexity of
processes affecting these CL species, I first analyzed the data from the perspective of CL
fatty acid chain concentrations, an approach that reduces the dimensionality of the prob-
lem. As an initial question, I investigated whether the four acyl chain positions of CL
are independently and identically remodeled. To test this, I built an "Independent and
Identical Distribution" (IID) model, in which the relative frequency of a CL isomer is the
product of the probabilities of its four fatty acid chains, Equation 2.3. The probability
of a CL molecular species is the sum over all isomers with the same number of total
carbons and double bonds, Equation 2.4. The FA distribution at the CL chain positions,
{ PCL(α1),PCL(α2), · · · ,PCL(αn) } (αi are chain types found among acyl donors PC sn-2,
PE sn-2, PG, and acyl CoA), is predicted by minimizing the error between the predicted
and observed CL molecular species distribution, Equation 2.5. If IID behavior is consistent
with the remodeling processes within a sample, there should exist a FA distribution that
can reproduce the experimentally observed CL profile when Equation 2.3 is applied.
Table 2.10 shows the least error and Pearson correlation coefficient between the ob-
served and optimally fit CL distribution. 13/14 mouse brain samples yield r > 0.7. A sec-
ond set of B6 measurements for brain, heart, lung, and liver also yield r > 0.9. The results
54
suggest that in general, the four chain positions of CL are independently and identically
remodeled. To test the robustness of the IID model, I performed four-fold cross validation,
see Method. The correlation coefficients in the cross-validation were still strongly posi-
tive, though somewhat lower than for the original data. This is not unexpected since each
CL peak contains information about only a few FA chains, and the cross-validation uses
only subsets of the peaks at a time. However all samples and tissues achieved much higher
correlation coefficients compared to random label-permuted data (t-test p-value<0.05) in-
dicating that the IID model could accurately describe CL remodeling behavior.
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Sample Error Pearson Correlation Cross validation results
Pearson Correlation (p-
value)
B6 brain 0.0014 0.9745 0.91±0.01 (4.0E-06)
B6 heart 0.0007 0.9969 0.78±0.16 (0.00054)
B6 lung 0.0030 0.9813 0.93±0.01 (9.0E-06)
B6 liver 0.0002 0.9997 0.99±0.00 (3.6E-08)
B6 (additional measure) 0.0010 0.9845 0.96±0.01 (4.0E-05)
VM 0.0143 0.8437 0.66±0.09 (0.00019)
CT2A vivo 0.0213 0.7245 0.39±0.20 (0.019)
EPEN vivo 0.0080 0.8736 0.58±0.12 (0.00062)
VM M2 vivo 0.0150 0.7722 0.60±0.06 (0.00034)
VM M3 vivo 0.0158 0.7416 0.36±0.09 (0.0012)
VM NM1 vivo 0.0126 0.8828 0.36±0.10 (0.0031)
BV2 vitro 0.0088 0.8465 0.49±0.17 (0.0032)
Astrocyte vitro 0.0061 0.9206 0.46±0.27 (0.018)
CT2A vitro 0.0053 0.9158 0.77±0.04 (1.4E-05)
EPEN vitro 0.0043 0.9205 0.75±0.03 (0.0018)
VM M2 vitro 0.0067 0.8451 0.65±0.05 (0.0075)
VM M3 vitro 0.0192 0.5804 0.31±0.09 (0.0068)
VM NM1 vitro 0.0059 0.8908 0.73±0.12 (0.00037)
Table 2.10: The independent and identical distribution model successfully predicts CL
distributions. Quality of fit was assessed by squared-error between the fit and observed
CL distributions (column 2) as well as the Pearson correlation r of the fit and observed CL
data (column 3). 17/18 samples show r > 0.7. The 4th column shows Pearson correlation
of the fit and observed CL distributions in four-fold cross-validation (mean ± standard
deviation). These results demonstrate the model′s ability to predict the output using only
the attributes in a given subset. P-values compare the cross-validation correlation values
to correlations calculated on CL data with the labels randomly permuted (1-tail t-test). All
samples achieved p-value<0.05 indicating that the IID model could correctly describe the
CL remodeling system.
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The predicted FA compositions of CL for each tissue are shown in Figure 2.2 orga-
nized into clusters. According to our inference the predominant FA in mouse brain is 18:1
(∼ 48%). This is in contrast to heart, liver and lung, for which 18:2 is the predominant
component (∼ 70%). However, 18:1 is reduced in tumor samples, in particular lower in
VM M2 vitro, VM M3 vivo, and VM M3 vitro. I also observed that the level of 16:0 is
elevated in tumor samples and cell cultures (> 10%), compared to that in the B6 and VM
brain samples (∼ 2%).
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Figure 2.2: Comparison of CL FA compositions between 14 normal and tumor sam-
ples of mouse brain (A), as well as 4 mouse normal tissues (B). Oleic acid (18:1) is pre-
dominant in brain (∼40%), while its percentage is reduced in some tumor samples (e.g.,
VM M2 vitro, VM M3 vivo VM M3 vitro). Linoleic acid (18:2) is predominant in heart,
lung, and liver (∼70%).
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2.4.3 Acyl chains are proportionally incorporated in steady state
To investigate the formation of acyl chain compositions in CL, I then tested a "proportional
incorporation" model which is a refinement of the IID model. The proportional incorpora-
tion hypothesis is that that fatty acid incorporation rates are controlled by the head group
of the donor class (PC, PE, PG or acyl CoA) and that FAs within an acyl donor class are
indistinguishable to the remodeling enzymes. Under such a mechanism FAs would be in-
corporated into CL proportionally to their prevalence in the donor class. If this hypothesis
is correct, the number of parameters in the CL remodeling system can be reduced to the
number of acyl donor classes.
For the brain samples, I investigated a model with weight parameters WPC, WPE , and
WPG, Equation 2.8. These parameters indicate the relative contributions of each lipid class
to CL FA composition in steady state. For each sample, I then searched for optimal param-
eter values that could explain the CL acyl chain composition. I successfully found weight
parameters for 11/14 mouse brain samples with strong correlation coefficient (r > 0.7) and
significant p-values (p<0.05). I also investigated the proportional incorporation model with
an additional acyl CoA weight parameter for the heart, lung, liver, and additional B6 brain
sample, for which experimental acyl CoA distributions were available. Among these tis-
sues, liver and brain showed a good fit (r > 0.7) with the proportional incorporation model.
Thus the simple proportional incorporation model describes CL remodeling in most tissues,
despite the varying CL profiles in different samples/tissues. This suggests that PC and PE
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transacylation remodeling has little chain specificity within each class. In brain and liver,
transacylation is the dominant remodeling process, as our analysis indicates that the acyl
CoA contribution is zero (Table 2.11).
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Sample WPG WPC WPE WAC Pearson p-value
(Pear-
son)
Error p-value
(Error)
B6 brain 0.2869 0.7131 0 0 0.8893 0.0042 0.0415 0.0039
B6 heart 0 0.2212 0 0.7788 0.5069 0.2267 0.3358 0.2313
B6 lung 0 1 0 0 0.5490 0.1724 0.2624 0.1647
B6 liver 0 1 0 0 0.7859 0.0157 0.2889 0.0131
B6 (additional
measure)
0 1 0 - 0.8936 0.0024 0.0494 0.0024
VM 0.4823 0.481 0.0367 - 0.7726 0.0143 0.1105 0.0111
CT2A vivo 0.6631 0.0262 0.3108 - 0.8498 0.0038 0.0532 0.0029
EPEN vivo 0.4261 0.3887 0.1852 - 0.9384 0 0.0258 0
VM M2 vivo 0.5701 0 0.4299 - 0.9249 0.0004 0.0211 0.0002
VM M3 vivo 0 0.7419 0.2581 - -0.1189 0.8255 0.2201 0.9722
VM NM1 vivo 0.2284 0.7716 0 - 0.9428 0.0002 0.0451 0.0016
BV2 vitro 0.4471 0.3021 0.2508 - 0.8608 0.0132 0.052 0.0154
Astrocyte vitro 0.0956 0.9044 0 - 0.8868 0.0064 0.0538 0.0075
CT2A vitro 0 1 0 - 0.9117 0.0041 0.0361 0.0038
EPEN vitro 0.2767 0.7128 0.0105 - 0.9072 0.0012 0.0304 0.0008
VM M2 vitro 0.3741 0.3641 0.2619 - 0.4711 0.1468 0.1089 0.2433
VM M3 vitro 0 0.4694 0.5306 - 0.1829 0.4544 0.1572 0.6088
VM NM1 vitro 0.06 0.94 0 - 0.8619 0.0143 0.0464 0.0091
Table 2.11: Proportional incorporation model: inferred remodeling parameters and
performance. The optimal remodeling weights inferred via the proportional incorpora-
tion model are given for each sample for PC, PE, and PG, as well as for acyl CoA for
the four tissues where acyl coA data were available. The quality of fit was assessed by
Pearson correlation r and squared-error between the fit and observed CL acyl compositions
(columns 6 and 8). Most samples were successfully fit by the proportional incorporation
model (r > 0.7). P-values were assessed by comparing to results for label-permuted PC,
PE, PG, and acyl CoA FA data (columns 7 and 9).
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As can be seen in Table 2.11, in 10/18 samples, PC had the largest contribution to
the CL acyl chain compositions, with higher weight values compared to other acyl chain
donors. PE had the largest contribution in only 1/18 samples (VM NM1 vitro), and it had
the lowest contribution in 13/18, with lower weights values compared to other acyl chain
donors. For the four B6 tissues, our inference suggests that acyl CoA is the most important
acyl chain donor for CL in heart, which contributes 77.88% of CL remodeling. Whereas in
brain, lung and liver, other acyl donors were predicted to contribute much more than acyl
CoA in CL remodeling.
2.4.4 Deviations from the Proportional Incorporation Model
For samples where the proportional incorporation model failed to explain the CL profile
(VM M3 vivo r= -0.1189, VM M3 vitro r= 0.1829, VM M2 vitro r= 0.4711, B6 heart r=
0.5069, B6 lung r = 0.5490), a number of explanations are possible. One possibility is that
an additional remodeling enzyme has been utilized, altering the selectivity on chain types
within a donor class. In order to gain insight into which individual chain types are under
selection, I plotted FA composition residuals in the fit to the proportional incorporation
model (Figure 2.3). A positive residual indicates that there is an excess of the chain in CL
over that predicted by the proportional incorporation model, i.e. a remodeling enzyme may
favor that chain type, and vice versa for negative residuals. In the VM M3 vivo and VM
M3 vitro samples, 16:0, 18:0 and 22:5 are most expressed in CL and 18:1 is disfavored.
62
18:2 is preferentially incorporated in B6 heart, lung, and liver, but not in brain. 16:0, 20:4
and 22:6 are slightly disfavored across the four tissues. This residuals approach may be
useful for understanding the behavior of remodeling enzymes in aging, obesity, diabetes,
heart failure and in a rare genetic disease (Barth syndrome).
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Figure 2.3: FA residuals reveal potential enzyme selectivity. The y-axis shows the
residual between the FA composition best describing the CL data and the fit to this FA
composition by the proportional incorporation model. A positive residual suggests enzyme
preference. Box statistics are shown for 14 brain samples (A) and 4 B6 mouse tissues (B)
with median and 25th and 75th percentiles.
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2.5 Discussion
I have presented a novel, powerful computational method to infer CL remodeling mecha-
nisms from MDMS-SL data, which I expect to be critical for understanding CL metabolism.
New mechanistic inference methods are of great importance since lipidomic data, such as
those in the LIPID MAPS projects [66, 3, 4], are becoming increasingly abundant [67, 68].
We focused on synthesis and remodeling primarily within one class of lipids, CL, taking
advantage of the accuracy of MDMS-SL identification of individual CL molecular species.
In contrast, prior lipid computational analyses have tended to focus on broader character-
izations of lipid pathways, such as the relative abundance of the various classes of lipids
[60] or signal transduction leading to lipid changes [65]. Our focus on CL allowed us to in-
vestigate a mechanistic model having a very small number of fit parameters, which enabled
us to robustly determine and cross-validate the remodeling behavior in each sample.
Although CL displays tissue- and sample-specific distributions, 17/18 samples can be
explained by the IID model. For the sample that is not accurately described by the IID
model, i.e. VM M3 vitro, it is possible that a relatively uncommon mechanism become ac-
tive in this sample, which is specific to certain positions or may cause association between
acyl chain positions that violate IID assumptions. The model may also fail to explain the
data when the sample is composed of heterogeneous cell populations, which have distinct
CL acyl chain compositions. Further analysis is desirable to explore these possibilities.
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The proportional incorporation model also fits 11/14 brain samples as well as the extra
B6 brain and liver samples, which is surprising given the model’s simplicity. The success
of the proportional incorporation model suggests that in these tissues, the headgroups on
acyl donors are the main determinants of contribution to CL, rather than selectivity on
individual acyl chains. This is consistent with previous studies indicating that the activities
of remodeling enzymes such as PLA2 are determined by interactions on the bilayer surface
rather than the hydrophobic interior [88]. I also observe that PC in general contributes
more to CL than the other donor classes. Although the mechanism for this is unclear, the
classical surface dilution model [54] suggests this may be an indication of domains within
the mitochondrial membrane of greater PC concentration, to which remodeling enzymes
may bind more easily. If there is selectivity on the acyl chains, we speculate this may more
commonly arise within acyl CoA-related mechanisms. This is because the proportional
incorporation model works well even for many tissues for which acyl CoA data were not
available, This is consistent with PC and PE contributing proportionally while acyl CoA is
subject to more specific regulation.
Interestingly, when I did observe deviation from the IID behavior, these deviations had
certain regularities. For example, the CL peaks at 80:14 and 80:15 (species name refers
to number of total carbons and double bonds) are consistently underestimated in the BV2
vitro, VM M3 vitro, VM, and CT2A vivo samples (Figure 2.4). The regularity of such
deviations suggests there are remodeling mechanisms that can distinguish the four positions
or which involve positional dependencies.
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Figure 2.4: Trends of deviation from the IID model. Certain CL species appear to
consistently deviate from the IID model, notably 80:14 and 80:15 (marked with *). (A)
BV2 vitro (r = 0.8465), (B) VM M3 vitro (r = 0.5804), (C) VM (r = 0.8437) and (D) CT2A
vivo (r = 0.7245).
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One simple way the chain positions could be distinguished is by their sn-1 or sn-2
chemistry. I examined this by modifying the IID model to an "independent and differential
distribution" (IDD) model that distinguishes sn-1 vs. sn-2 positions. However, this modifi-
cation provided little improvement in the fit. Only the VM-NM1 vivo sample showed sig-
nificant improvement (p-value<0.05; see Methods). This suggests that the unusual peaks
at 80:14 and 80:15 are controlled by dependencies between positions, rather than indepen-
dent but differential behavior. This behavioral equivalence between sn-1 and sn-2 in CL is
surprising given that remodeling reactions acting on diacyl phospholipids (PC, PE, PG, PI)
have a bias for the sn-2 position [89].
A minor caveat to our CL analysis is that it is based on the concentrations of CL peaks
as defined by the number of carbons and double bonds among the acyl chains. Some
lipidomic measurement methods such as MDMS-SL provide additional information about
species distributions within each peak. Such information is irregular and with different
uncertainties across peaks, making it difficult to use, but future methods may benefit from
it.
Also, the model I have described here pertains to steady-state behavior. This is appro-
priate since all of the samples I have analyzed are under steady-state conditions. Therefore
enzyme specificities impact our model as they would affect equilibrium constants in typical
chemical systems (see Methods). Parameter inference for the dynamics of CL remodeling
is a valuable future goal. In Chapter 4, I describe a network inference method for glyc-
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erophospholipid flux analysis using experimental timecourse data. The framework shows
promise of being a powerful tool for the future study of CL dynamic remodeling processes.
Because of the tradeoff between complexity and robustness of the inferred model [90],
I have studied simplified models which are approximations of the behavior of CL. Aside
from a generalization to handle dynamic data, further refinements may include parameters
for more nuanced distinctions among donor classes. Such distinctions may be important for
understanding individual enzymes such as tafazzin, which influences the transfer of chains
from PC to CL [53]. Other important factors may include the relative positions of PC,
PE, and PG in the CL remodeling pathway [40, 91, 92], molecular symmetry preferences
[93, 94], or transfer of lipids among membranes. Through careful consideration of such
refinements, I believe that our mechanistic inference method will generalize to other classes
of lipids, providing a broad approach to analyzing diseases associated with alterations of
lipid metabolism.
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Chapter 3
Statistical analysis of the processes
controlling choline and ethanolamine
glycerophospholipid molecular species
composition
3.1 Introduction
Glycerophospholipids comprise the vast majority of membrane lipid content. Each is
composed of a glycerol backbone, a head group esterified to a phosphate that connects
70
to the glycerol at the sn3 position, and acyl chains located at the sn1 and the sn2 posi-
tions of the glycerol [16]. Multidimensional mass spectrometry-based shotgun lipidomics
(MDMS-SL) using dimensional, chemical, and computational strategies have shown that
lipid molecular species have diverse, highly regulated acyl chains at specific positions
[6, 7]. The distribution and content of molecular species are selectively regulated by the
complex homeostatic balance of biosynthesis, remodeling (transacylase or acyltransferase),
and catabolism [17, 18].
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Figure 3.1: Basic composition of a diacyl glycerophospholipid. Fatty acids are attached
to the sn1 and sn2 positions of the glycerol backbone. The polar head groups are attached
to the sn3 positions and can be a number of substituents that distinguish the different phos-
pholipid classes. (reprinted from [95])
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In the vast majority of tissues and membranes, the two most abundant glycerophos-
pholipids are PC and PE. It is roughly known that shorter, saturated acyl chains are lo-
calized in the sn1 positions and longer, more unsaturated acyl chains are enriched in the
sn2 positions, likely due to biophysical stringency and positional functional recognition by
phospholipases. However, such characterizations of PC and PE acyl chains have not been
analyzed in any statistical framework, in spite of the fact that high-throughput lipidomic
data are now available. Lipidomic data provide an opportunity for rigorous identification
of PC and PE acyl chain behaviors, a vital step in determination of mechanisms of acyl
chain regulation.
Processes controlling species composition have been described in Chapter 2 for the
tetra-acyl phospholipid cardiolipin, in the context of a simplified model of independent
and identical behavior of the acyl chains. However, the extent of cooperative interactions
among acyl chains within a single phospholipid (e.g. cooperation between sn1 and sn2
positions, an idea proposed for cardiolipin by Schlame et al [96]) is poorly understood.
Quantification of phospholipid acyl behaviors is vital for understanding the regulation of
biochemical functions controlled by phospholipids. Knowledge of these behaviors will
also improve detection of molecular species lying just below current limits of lipidomic
measurement technology via cryptanalytical approaches that combine chemical detection
with computational simulation of acyl chain remodeling behaviors [10].
In this Chapter, I present a computational analysis of the dependence between acyl
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chains in the phosphatidylcholine and phosphatidylethanolamine molecular species, (in
collaboration with Dr. Kourosh Zarringhalam at Boston College). PC and PE are critical
molecules because of their dominance in the phospholipid composition of cellular mem-
branes. Also because these molecules each have only two acyl chains, they are the simplest
types of lipids for which to investigate cooperative effects. This study analyzes MDMS-SL
measurements of mitochondrial PC and PE in mouse heart development (at days 1, 7, 14,
21, 28, 35, and 120) as well as three other mature mouse tissues (brain, lung, liver).
I demonstrate several key findings. In PC and PE, sn1 and sn2 positions are largely
independent, though for low abundance species there may be processes controlling species
composition that involve both the sn1 and sn2 chains simultaneously, leading to cooperative
effects. Chains with similar biochemical properties appear to be regulated similarly. The
regulation of the sn2 position is also more complex than at the sn1, and that PC exhibits
stronger cooperative effects than PE.
The distributions of fatty acids being analyzed are the result of the homeostatic balance
between the rates of biosynthesis, acyl-chain remodeling, and degradation, as well as the
spectrum of fatty acids available. Since the samples we study are not connected by an
explicit mechanistic process, these statistical analyses describe the aggregate effect of all
processes, rather than distinguishing individual effects. A key aspect of this research is a
novel statistically rigorous approach to determine whether chains at the sn1 and sn2 po-
sitions behave cooperatively based on contingency tables and Markov Chain Monte Carlo
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sampling. Thus by application of multiple computational approaches to lipidomic data we
are able to determine the dependence between the sn1 and sn2 positions in choline and
ethanolamine glycerophospholipids, quantifying the stringent molecular species regulation
of these dominant lipid classes.
3.2 Methods
3.2.1 MDMS-SL quantification of lipids
Individual lipid extracts were reconstituted with 1:1 (v/v) CHCl3/CH3OH, flushed with
nitrogen, and stored at −20◦C prior to electrospray ionization-MS using a TSQ Quantum
Ultra Plus triple-quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, CA)
equipped with an automated nanospray apparatus (Advion Biosciences Ltd., Ithica, NY)
and customized sequence subroutine operated under Xcalibur software. For each tissue
type, 3-4 biological replicates were performed. C57BL/6J (B6) mice were euthanized at
indicated ages during development or at 4 months of age. Tissues were excised, briefly
washed in 10X diluted PBS and immediately freeze clamped using liquid nitrogen. All
animal procedures were performed in accordance with the Guide for the Care and Use of
Laboratory Animals and were approved by the Animals Studies Committee at Washington
University School of Medicine.
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3.2.2 Identification of individual lipid molecular species
Lipidomic analysis was performed as previously described [7, 10, 11] and will be briefly
described as follows. Both isobaric and isomeric species have the same nominal mass and
therefore overlap in the spectrum acquired on a low to moderately high accuracy/resolution
mass spectrometer. Isobaric lipid species are normally from different lipid classes and
therefore have different head groups and thus different acyl composition (e.g., protonated
16:1-22:6 diacyl PE and 16:0-18:0 diacyl PC have different acyl composition but the same
nominal mass of 762). Isomeric lipid species are from the same lipid class and therefore
have identical acyl composition (e.g., 18:0-18:2 diacyl PE and 18:1-18:1 diacyl PE have
identical acyl composition, i.e. total carbon number of 36 and total double bond number of
2).
In MDMS-SL, generally each lipid class or category is first selectively ionized through
intrasource separation followed by a class-specific diagnostic scan to generate an ion peak
list of the molecular species in a lipid class of interest for further acyl chain identification.
This list is generated by matching the m/z values of the detected ion peaks in the diagnos-
tic scan with those of the candidate species in the pre-established virtual database of the
lipid class of interest. The list therefore contains information about the total number of
carbon atoms and the total number of double bonds of the acyl chains. The presence of
isobaric species, unlike the presence of isomeric species, does not affect acyl chain identi-
fication due to their differential total carbon number and total double bond number which
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discriminate them.
There are two types of isomeric lipid species, i.e., the acyl chain compositional isomers
(e.g., 18:0-18:2 diacyl PE and 18:1-18:1 diacyl PE) and the regioisomers (e.g., 18:0-18:2
diacyl PE and 18:2-18:0 diacyl PE). The sum of the intensities of the paired acyl carboxy-
lates in their corresponding PIS or in product ion scans in negative ion mode is used to
assign the ratio between the acyl chain compositional isomers. For example, if the ratio of
the sum of the intensities of 18:0 and 18:2 carboxylates to the intensity of 18:1 carboxylate
is 2:1, then the 18:0-18:2 and 18:2-18:0 diacyl PE is 67%, and the 18:1-18:1 diacyl PE is
33%.
The regioisomer ratio is assessed by the ratio of the intensities of the paired acyl car-
boxylates. The ratio of sn1 and sn2 acyl carboxylates in each lipid class or subclass is pre-
determined by extensive examination of numerous product ion spectra of synthetic lipid
standards with known sn1 and sn2 acyl chain composition. For example, the ratios of sn2
to sn1 acyl carboxylates are found to range from 2.27 to 3.77 and center at 2.94± 0.4 for
molecular species in diacyl PE class (See Figure 3.2).
77
1
6
:
0
−
1
8
:
1
1
6
:
0
−
2
2
:
6
1
8
:
0
−
1
8
:
2
1
8
:
0
−
1
8
:
2
1
8
:
0
−
2
0
:
4
1
8
:
0
−
2
0
:
4
1
8
:
0
−
2
0
:
5
1
8
:
0
−
2
2
:
4
1
8
:
0
−
2
2
:
5
1
8
:
0
−
2
2
:
6
1
8
:
0
−
2
2
:
6
1
8
:
1
−
1
8
:
2
1
8
:
1
−
2
0
:
4
1
8
:
1
−
2
0
:
4
1
8
:
1
−
2
2
:
4
1
8
:
1
−
2
2
:
5
1
8
:
2
−
2
0
:
4
1
8
:
2
−
2
2
:
4
synthetic PE sn2/sn1 ratios
0.0
2.27
2.94
3.77
s
n
2
/
s
n
1
 
r
a
t
i
o
Figure 3.2: PE sn2/sn1 ratios. The ratio of sn1 and sn2 acyl carboxylates in each lipid
class or subclass is pre-determined by extensive examination of numerous product ion spec-
tra of synthetic lipid standards with known sn1 and sn2 acyl chain composition.
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If the intensity ratio of 18:2 carboxylate to 18:0 carboxylate is 3 or larger in the above
example, this PE species is identified as 18:0-18:2 diacyl PE and therefore the final assign-
ment for this example is 18:0-18:2/18:1-18:1 at 67%/33%. If the intensity ratio of 18:2
carboxylate to 18:0 carboxylate is 0.3 or less, this PE species is identified as 18:2-18:0
diacyl PE and therefore the final assignment is 18:2-18:0/18:1-18:1 at 67%/33%. If the
intensity ratio of 18:2 carboxylate to 18:0 carboxylate is between 0.3 to 3, the regioiso-
mers of 18:0-18:2 and 18:2-18:0 are both present. For example, if the intensity ratio is 2,
the relative fractions of 18:0-18:2 and 18:2-18:0 are 83%/17% and the final assignment is
18:0-18:2/18:2-18:0/18:1-18:1 at 56%/11%/33%. The details of the method as well as the
effect of using a different threshold value (i.e., other than 3) on the subsequent statistical
analysis are discussed later.
Two corrections are specifically considered for the determination of the intensities of
carboxylates. One is the correction of the effect of 13C isotopologue on the carboxylate
intensities as previously described [8]. Another is the correction for the reduced abundance
of fatty acyl carboxylate containing multiple double bonds (e.g., 22:6, 20:4 and 18:3 with
a total double bond number of 3 or larger ) due to the facile loss of CO2 during collision
induced dissociation (CID) in tandem mass spectrometry as previously demonstrated [7].
The analyzed spectroscopic molecular species datasets are provided. The relative abun-
dances of isomers listed for a species were calculated as described above and annotated for
mature heart, brain, lung, and liver. For the heart developmental data, the relative abun-
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dances of isomers were homogeneously estimated based on the described procedure. The
relative abundances of isomeric species were approximated as 75%/25%, 64%/27%/9%,
50%/21%/21%/8% for di-, tri-, and tetra- isomers respectively.
3.2.3 Positional independence model
Let T denote a phospholipid with two fatty acid chains (i.e. PC or PE). Assume that Ω =
{α1, · · · ,αN} is the pool of possible fatty acid chain types that can be incorporated in either
the sn1 or the sn2 positions of T . Incorporation of the fatty acid chains in the sn1 and
the sn2 positions of T can be viewed as random processes, with random variables X and
Y for the processes in the two respective positions. The joint random variable (X ,Y ) is
distributed on the sample space Ω×Ω.
Let
{
pii j
}
denote the joint probability Pr(X = αi,Y = α j), which can be obtained from
the experimental concentration of the PC (or PE) species with chains (X = αi,Y = α j)
normalized so that they sum to 1. Denote the marginal probabilities by {pii+} and
{
pi+ j
}
,
where pii+ = ∑ j pii j and pi+ j = ∑ipii j. If the random variables X and Y are independent, the
joint probabilities should equal the product of their marginals. We wish to distinguish the
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null hypothesis of independence from the alternative hypothesis of cooperativity:
H0 : pii j = pii+pi+ j
H1 : pii j 6= pii+pi+ j
for all i and j. Sufficient statistics under the null hypothesis of independence are the column
and row marginals.
To test the independence model, it is necessary to consider the measurement uncertainty
in the pii j and determine whether deviations from pii j = pii+pi+ j are statistically significant.
For a given tissue type, the mean pˆii j and standard deviation σˆi j were calculated for each i j
using the replicates for the tissue type. We modeled the variation in pii j across replicates by
a binomial process whose effective sample size would give the observed standard deviation.
To determine this effective sample size, we calculated the variance effective sample size for
each species i j as
ni j =
pˆii j(1− pˆii j)
σˆ2i j
(3.1)
We then averaged these values of ni j over all i j to get an effective sample size n for
the tissue type. For this averaging, outlier values of ni j were excluded at the significance
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level of 0.1, based on an assumed normal distribution for the ni j values. In the resulting
model, probabilities pˆii j correspond to absolute counts µi j representing the total number of
sampled molecules for each i j in the tissue type.
For each tissue type, we then simulated 15 sets of values for the µi j using pˆii j as weights
and n as the number of sampled molecules with a multinomial sampling process. For each
of these simulated sets, the positional independence model was then evaluated by perform-
ing the Fisher’s exact test. The p-value in the Fisher’s test was calculated by summing
the probabilities of all permissible tables with equal or more extreme arrangement than
the observed table [97, 98]. In cases where n is large, it is impractical to enumerate all
possible tables. Thus Markov Chain Monte Carlo (MCMC) was used to explore the space
of permissible tables and approximate the p-value [98]. In our implementation, we used
the R package aylmer.test and 10000 permissible tables were generated in the MCMC
simulations to calculate the p-values. In the MCMC procedure, cells with zero counts were
kept fixed. For each tissue type, the p-value for independence was reported as the average
of the p-values of the 15 simulated sets.
For testing of the quasi-independence model, we selected subsets of chain types at
the sn1 and sn2 positions. The subsequent statistical test was performed on the partial
frequency table as described above.
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3.2.4 Variance effective sample size
In order to estimate the variance effective sample size, we regard each peak k, in the MS
data as an independent observation of a binomial process corresponding to the observed
species k. Note that k corresponds to the species i j in the Methods. Given L biological
replicates, let the effective sample size and the counts of the corresponding specie for the
kth peak and the `th replicate be nk and mk` respectively. The estimated probability of the
kth species in the `th replicate is then pik` = mk`nk . Let
pˆik =
1
L
L
∑`
=1
pik` =
1
L
L
∑`
=1
mk`
nk
=
1
nk
(
1
L
L
∑`
=1
mk`
)
=
mk
nk
(3.2)
be the average probability of of the kth species across the replicates. Here mk is the
average count of the kth species. Let sk be the standard deviation of the counts. For the
binomial model sk =
√
nkpˆik(1− pˆik). On the other hand, if σˆk denotes the sample standard
deviation of the probabilities, then
σˆk =
√
1
L
L
∑`
=1
(pik`− pˆik)2 = 1nk
√
1
L
L
∑`
=1
(mk`−mk)2 = sknk (3.3)
From above equation it follows that
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nk =
pˆik(1− pˆik)
σˆ2k
(3.4)
We then averaged these values of nk over all k to get an effective sample size n for the
tissue type. For this averaging, outlier values of nk were excluded at the significance level
of 0.1, based on an assumed normal distribution for the nk values.
3.2.5 Clustering Analysis
The conditional probability Pr(Y = β |X = α) = Pr(X=α,Y=β )Pr(X=α) describes the probability of
observing chain type β at the sn2 position given that chain type α is at the sn1 position.
I performed clustering on the conditional distributions to determine whether there are acyl
chains in the sn1 position that influence chains at the sn2 position in the same way. To
do this clustering, for every pair of sn1 chain types I measured the distance between their
sn2 conditional distributions, Pr(Y = β |X = α1) and Pr(Y = β |X = α2), using Jensen-
Shannon Divergence. I then performed UPGMA (Unweighted average distance) clustering
on the distance matrix. By examining the clustering from all tissue types, which showed
similarities, I defined a set of canonical/noncanonical chains types at each of the sn1 and
sn2 positions.
In the test of quasi-independence, I selected a set Ωsn1 of the 2 most similar sn1 canon-
ical chain types for a given tissue type. A second clustering of sn2 canonical chain types
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was performed based on sn1 conditional distributions, i.e., Pr(X = α|Y = β ) for α ∈Ωsn1.
All pairs of clustered sn2 chain types Ωsn2 were considered. Tests of independence were
performed on these subsets. For any subset where the null hypothesis was not rejected
at threshold p-value 0.05, I continued searching for a larger subset by including the next
closest sn1 or sn2 chain types.
3.2.6 Deviation from Independence
The deviation of each i j from the independence model was quantified by the standardized
residual
di j =
Oi j− µˆi j
σˆi j
=
Oi j− µˆi j√
µˆi j
(3.5)
where Oi j denotes the observed frequency and µˆi j denotes the expected frequency of the
cell (i, j). Note that here, the counts in the table are modeled as realizations of an indepen-
dent Poisson random variable. This is equivalent to testing the hypothesis of independence
in a multinomial model [97].
3.2.7 Jensen-Shannon Divergence
Jensen-Shannon Divergence (JSD) is a statistical measure of the divergence of two or more
probability distributions. I used JSD to compare multiple phospholipid distributions as:
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J (P1,P2, · · · ,Pm) = H(
m
∑
j=1
ω jP j)−
m
∑
j=1
ω jH(P j), (3.6)
Here H(P) =−∑i pi log2(pi) is the Shannon entropy, P1,P2, · · · ,Pm are the probability
distributions, and ~ω = (ω1,ω2, · · · ,ωm) is a vector of weights with ω j > 0, ∑mj=1ω j = 1.
For the comparison of the observed and the independence distributions, m = 2 and the
weights are assigned uniformly i.e., ~ω = (12 ,
1
2). For comparing the observed distribution
across the tissues (mature heart, brain, lung, and liver), m = 4 and the weights are assigned
equally as well, i.e., ~ω = (14 ,
1
4 ,
1
4 ,
1
4).
For the comparisons of the marginal distributions across time points, the weights were
scaled to be proportional to the interval between the successive time points, i.e. ω j =
∆Tj
∑mj=1∆Tj
. More specifically, given time points T = 1,7,14,17,21,28,35, the computed
weights were ~ω = ( 135 ,
6
35 ,
7
35 ,
3
35 ,
4
35 ,
7
35 ,
7
35). This scaling allows us to take the timespans
at which the lipid concentrations were measured into consideration and attain an unbiased
evaluation of the changes in the molecular species profiles.
3.3 Results
We statistically analyzed lipidomic data for PC and PE in mitochondria from 11 types of
mouse tissues. These were brain, heart, lung, and liver from 4 month old C57BL/6J(B6)
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WT mice; and developing heart from C57BL/6J(B6) WT mice at 1, 7, 14, 17, 21, 28,
and 35 days of age [10]. Each tissue type was measured in 3-4 biological replicates. For
each tissue type, the probability distribution for lipid molecular species was calculated by
normalizing concentrations to sum to one and averaging among replicates. This yielded
probabilities for molecular species with X at the sn1 position and Y at the sn2 position
Pr(X ,Y ).
3.3.1 Characterization of phospholipid sn1 and sn2 marginal distri-
butions
The distributions of fatty acids at the sn1 and the sn2 positions of phospholipid provide
valuable information about the processes controlling species composition. The marginal
distribution at the sn1 position quantifies the acyl composition at the sn1 irrespective of the
sn2, and vice versa for the marginal distribution at the sn2 position. For each tissue type and
lipid class we calculated the marginal probability of observing chain β at the sn2 position
as Pr(Y = β ) = ∑α Pr(X = α,Y = β ) as well as the marginal probability of observing α
at the sn1 position Pr(X = α) = ∑β Pr(X = α,Y = β ).
Comparing PC and PE marginal distributions, I found that they are generally similar.
For both types of molecules, the predominant fatty acids at the sn1 position are 16:0 and
18:0, while the fatty acids at the sn2 position are generally the longer and unsaturated fatty
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acid chains 18:2, 20:4, and 22:6. This is consistent with many previous findings [31, 99,
100]. However, PC and PE marginal distributions display different levels of similarities
across samples.
To quantify similarities between PC and PE, I measured Jensen-Shannon Divergence
(JSD) between PC and PE marginal distributions for each sample and at each sn position.
JSD measures the dissimilarity between probability distributions symmetrically with values
ranging from 0 (when distributions are identical) to 1 [101]. PC vs. PE comparisons for
all samples are shown in Figure 3.3. In general, PC and PE are more similar at the sn1
position than at the sn2 position. In 9/11 tissues, the sn1 JSD is lower than the sn2 JSD.
The exceptions are for mature heart and mature brain. The sn2 acyl distributions of mature
heart PC and PE have the lowest JSD of any comparison (JSD=0.070). This is likely due to
the presence of the dominant 20:4 and 22:6 acyl chains which tend to highly localize in the
sn2 position in both PC and PE. However, for mature brain, the sn1 acyl distributions have
the second highest JSD of any comparison (JSD=0.261), likely because of the presence of
more monounsaturated acyl chains (e.g. 18:1) in brain PC than in brain PE. It is worth
noting that for all comparisons, the JSDs are low on an absolute scale (max. 0.266 for
sn2 lung). This indicates that, despite some small variations by tissue type, PC and PE are
largely regulated by similar processes (also see Figure 3.4). Thus, PC and PE appear to be
governed by a common set of constitutive acyl chain regulatory processes, with distinctions
from this behavior occurring only occasionally in specific tissue types.
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Figure 3.3: Jensen-Shannon divergence of PC and PE marginal acyl distributions. For
each of sn1 (A) and sn2 (B) positions, the dissimilarity between PC and PE marginal acyl
distributions was measured by Jensen-Shannon Divergence (JSD). The highest similarity
was observed for mature heart sn2 (JSD = 0.07), while the lowest similarity was observed
for mature lung sn2 (JSD = 0.266). A trend of decreasing JSD was observed during heart
development from day 7 to day 35, for both sn1 (R2 = 0.9439, β = −0.00187) and sn2
(R2 = 0.6678, β =−0.00078).
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Figure 3.4: PC and PE acyl chain marginal probabilities during heart development.
Trajectories of marginal probabilities of PC (red circles) and PE (blue triangles) for sn1
16:0 (A), sn1 18:0 (B), sn2 20:4 (C), and sn2 22:6 (D). PC and PE marginal probabilities
closely follow each other in B, C, and D, suggesting these chain types are substrates of these
two phospholipids’ shared processes controlling species composition. The two curves in A
are divergent, indicating that acyl chain remodeling of sn1 16:0 in PC and PE differs.
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Interestingly, I observed a trend of PC and PE becoming more similar during heart de-
velopment from day 7 to day 35. This can be seen by the decrease in JSD with time at both
the sn1 (R2 = 0.9439) and sn2 (R2 = 0.6678) positions. However, the mechanisms leading
to this increased similarity of PC and PE differ by position. The slope of change at the sn2
position (β = −0.00187) is much smaller than that at the sn1 position (β = −0.00078).
It is notable that the day 1 sn1 JSD is unusually low relative to the other sn1 timepoints.
This is likely due to stronger maternal bias and the presence of dominant nascent immature
species containing less unsaturated acyl chains at day 1, with subsequent days reflecting
the processes controlling species composition activated during development.
To better understand the processes that distinguish PC and PE, we examined the trajec-
tory of marginals during heart development. Figure 3.4 shows the PC and PE marginals for
two abundant chain types at the sn1 position (16:0, 18:0) as well as the two abundant chain
types at the sn2 position (20:4, 22:6). The general similarity in processes controlling PC
and PE species composition can be seen in the trajectories for the sn1 18:0, sn2 20:4, and
sn2 22:6 marginals. All 3 of these marginals track closely between PC and PE, suggesting
that they are substrates of the two phospholipids’ shared regulatory processes. However,
the PC and PE sn1 16:0 curves diverge during development. This suggests that a process
specific to 16:0 chains in the sn1 position becomes active during heart development, and
that this process acts distinctly for PC and PE. Thus comparative consideration of marginals
can be used to reveal the existence of tissue- and acyl-specific regulatory processes.
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3.3.2 Characterization of phospholipid sn1-sn2 conditional distribu-
tions
We next investigated cooperative effects between sn1 and sn2 positions, i.e. whether a
particular chain at one position influences the distribution of chains at the other position. To
evaluate association between the positions, I considered the conditional probability Pr(Y =
β |X = α), i.e. the distribution of chains β at the sn2 position given chain α at the sn1
position. Figure 3.5(C) shows conditional distributions of the sn2 chains given the sn1
chain for PC mature heart. These conditional distributions vary greatly depending on the
sn1 chain. For example, when the sn1 chain is 18:2, the major sn2 chain is 22:6. However,
when the sn1 chain is 18:3, the predominant sn2 chain is 18:2. This suggests that for
specific class of sn1 chains, the enzymes involved in regulatory processes at the sn2 position
also interact with the acyl chain at the sn1 position.
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Figure 3.5: Conditional distributions and clustering of acyl chains. For PC mature
heart, a set of sn1 chain types Ωsn1 = {16:0 ,18:0 ,18:1 ,18:2 } (C) and a set of sn2 chain
types Ωsn2 = {16:0, 18:1, 18:2, 20:3, 20:4, 22:5, 22:6} (D) were each clustered. Within
each of these clusters, conditional acyl distributions were highly homogeneous. It is inter-
esting to note that at each of the sn1 and sn2 positions, the most abundant chains (panels A
and B) tend to be clustered together (panels C and D), indicating similar conditional effects.
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To investigate the similarity among these conditional relationships, I clustered the sn2
distributions Pr(Y = β |X =α) as a function of the sn1 chain (see Methods). Interestingly, a
group of sn1 chain types, Ωsn1 = {16:0, 18:0, 18:1, 18:2} display very similar conditional
sn2 distributions. For these sn1 chains, the predominant sn2 chain is always 22:6, with
smaller but consistent contributions from 20:4 and 18:1. Thus, while enzymes that regulate
the acyl chain at the sn2 position also recognize the acyl chain at the sn1 position, they are
indifferent among the sn1 chains in the set above.
I also considered the dependence Pr(X = α|Y = β ), with results for PC mature heart
shown in Figure 3.5(D). As expected, I observed that the sn2 chain affects the distribution
at the sn1 position (contrast Y=16:1 versus Y=22:6). However, I also saw groups of sn2
chains with comparable influence on the sn1 position. Clustering of Pr(X = α|Y = β ) by
β results in a set of chains Ωsn2 = {16:0, 18:1, 18:2, 20:3, 20:4, 22:5, 22:6} with similar
sn1 conditional distributions.
Similar behaviors were observed for all the tissue types studied, although the particular
conditional patterns vary from one sample to another (see Figure 3.6). Based on these
observations, I defined universal canonical chain types, {16:0, 16:1, 18:0, 18:1, 18:2} for
sn1 and {16:0, 18:1, 18:2, 20:0, 20:1, 20:3, 20:4, 20:5, 22:3, 22:4, 22:5, 22:6} for sn2
respectively, which tend to cluster together across samples. Remarkably, for most samples,
the canonical chain types include the most abundant chain types at the given position, such
as 16:0, 18:0 for sn1 and 18:2, 20:4, 22:6 for sn2. 16:0 and 18:0 are among the three most
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abundant chain types at the sn1 position for every tissue type and lipid class. 20:4 and 22:6
are among the three most abundant chain types at the sn2 position for 9/11 tissue types for
PC and 11/11 tissue types for PE. In general, there is only weak association between the
sn1 and the sn2 acyl chains when the most abundant canonical chain types are considered,
but for noncanonical chain types I observe stronger associations.
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(a) heart (b) liver
(c) brain (d) lung
Figure 3.6: Clustering of PC sn1 chain types.
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Predicted parameter values using randomly permuted 14:0-14:0 data do not converge.
Figure 3.7 shows the trajectories of the conditional probabilities Pr(Y = β |X = α) of
the four major sn2 chain types: 18:1, 18:2, 20:4, 22:6, given sn1 (α ∈Ωsn1) for PC during
heart development. Although these conditional probabilities show distinct behaviors as a
function of α at day 1, they converge by the time the mouse reaches maturity (day 120).
In particular, the distributions Pr(Y |X = 16 : 0) and Pr(Y |X = 18 : 0) show a striking sim-
ilarity, as these values (red and blue dots) are very close at all developmental timepoints
and for all sn2 chains. Similar behavior was observed for PE trajectories. 16:0 and 18:0
are notable because of their common biochemical characteristics of similar length and lack
of unsaturated bonds. These data indicate that the enzymes involved in controlling species
composition are indifferent among adjacent acyl chains with similar biochemical proper-
ties. I will describe the extent of this indifference in the next section.
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Figure 3.7: PC acyl chain conditional probabilities during heart development. The sn2
conditional probabilities given sn1 chain types, Ωsn1 = {16:0 ,18:0 ,18:1 ,18:2 } closely
follow each other. Shown are conditional probabilities for the four major sn2 chain types
18:1 (A), 18:2 (B), 20:4 (C), and 22:6 (D).
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3.3.3 Fisher’s exact test of independence between sn1 and sn2 chains
While the previous section suggests the existence of sn1-sn2 dependencies for acyl chains
with different biochemical properties, the hypothesis that sn1 and sn2 acyl chains influence
one another has not been directly tested. We can do this by comparing the experimentally
observed joint (X ,Y ) probability distribution for PC (or PE) to the product of the sn1 and
sn2 marginal distributions. Figure 3.8 shows heatmaps of the joint and product distributions
as well as their standardized residuals for the mature heart PC. The qualitative similarity
between the joint and the product distributions suggests that sn1 and sn2 chains will be
generally independent.
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Figure 3.8: Comparison of joint and product distributions for mature heart. Heatmaps
of the joint distribution (left), the independent product distribution (middle), and their stan-
dardized residual (right) for mature heart PC. The joint and the product distributions are
similar, suggesting that the acyl chains at the sn1 and the sn2 positions are largely indepen-
dent.
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To formally test independence, we designed a novel, statistically rigorous approach
based on the Fisher’s exact test. For the Fisher’s test it is necessary to use counts rather
than probabilities. Based on the mass of lipids analyzed, the number of molecules of PC or
PE in each sample can be estimated, which could in principle be used to scale probabilities
to counts. However, counts on this scale would be computationally infeasible for a Fisher’s
test, and this problem would be exacerbated by the disparate concentrations of species.
Therefore we instead mapped probabilities to counts using the variance effective sample
size (see Methods). This approach effectively makes use of the experimentally observed
variation in the data while allowing a reasonable computation time.
Note that the Fisher’s-based approach is necessary because more commonly used tests
of independence such as the Pearson’s χ2 test are unreliable on this type of data. Table
3.1 shows an example of the contingency table of mapped counts for PC mature heart
sample using the canonical chains. As can be seen, the table contains many species with
zero counts. The Pearson’s χ2 test of independence will not produce reliable p-values for
data with such zero counts. This is because the accuracy of the χ2 test is dependent on
asymptotic behavior of the Pearson’s χ2 test statistics, but this behavior often fails when
counts are low. The Fisher’s exact test provides an accurate alternative not affected by
such small counts. Another important consideration is that the variance effective sample
size n is in general still large, making it impractical to enumerate the entire permissible
tables. Therefore we used Markov Chain Monte Carlo (MCMC) to explore the space of
permissible tables and approximate the p-value.
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sn2
16:0 18:1 18:2 20:0 20:1 20:3 20:4 20:5 22:4 22:5 22:6
sn1
16:0 296 829 901 [0] 22 159 1212 107 [0] 612 7341
16:1 [0] 24 [0] [0] [0] [0] 7 [0] [0] [0] [0]
18:0 431 392 474 [0] [0] 120 1040 [0] [0] 324 6401
18:1 [0] 119 [0] [0] [0] 26 173 [0] [0] [0] 468
18:2 [0] 407 149 [0] 13 [0] 73 [0] [0] [0] 1066
Table 3.1: Two-way Contingency table for mature heart PC sample. The structural
zeros are denoted by [0]. The variance effective sample size is 24242.
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The results indicate the presence of cooperative effects between the sn1 and sn2 posi-
tions in all tissue types when all chains are considered. For each tissue type, we performed
the Fisher’s exact test to test the null hypothesis of independence of sn1 and sn2 positions,
with zero count cells kept fixed. We found that the null hypothesis of independence was
rejected at cut-off p-value of 0.05 for all tissue types when including all chain types in the
analysis. This indicates the presence of cooperative associations.
Given the general independence of sn1 and sn2 positions suggested by Figure 3.8, we
hypothesized that in each tissue the sn1 and sn2 position would be “quasi-independent",
i.e. there would be a few dependencies between individual classes of acyl chains, but there
would also be groups of chains for which the sn1 and sn2 positions are independent. To
determine groups of chains with such independence, I considered the sn1 and sn2 chains in
the canonical clusters Ωsn1 = {16:0, 16:1, 18:0, 18:1, 18:2} and Ωsn2 = {16:0, 18:1, 18:2,
20:0, 20:1, 20:3, 20:4, 20:5, 22:3, 22:4, 22:5, 22:6}. For each tissue type, we then tested
whether there is sufficient statistical evidence for independence among subsets of chains in
these canonical clusters.
To find these subsets we first selected the 2 closest sn1 canonical chain types, based on
their clusterings described in the previous section. We then performed the test of indepen-
dence on these 2 sn1 chains against all possible pairs of clustered canonical sn2 chain types.
For any subset where the null hypothesis was not rejected (significance level > 0.05), we
continued searching for a larger subset by adding the next closest sn1 or sn2 chain types
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and then testing independence again. In all tissue types, we found at least one subset of sn1
and sn2 chain types for which the independence hypothesis was not rejected. The subsets
contributing the most to the total concentrations are reported in Tables 3.2 and 3.3.
104
Sample
Name
Sample
Size
sn1 FA sn2 FA p-value % of
Total
Species
heart day 1 5949 16:0, 18:0 18:2, 20:3, 20:4,
22:5, 22:6
0.0637 31.91%
heart day 7 11148 16:0, 18:0 18:0, 18:2, 20:4, 22:6 0.1090 38.10%
heart day 14 6220 16:0, 18:0 18:0, 18:2, 20:4, 22:6 0.0724 39.80%
heart day 17 9333 16:0, 18:0 18:2, 22:6 0.3228 32.32%
heart day 21 3900 16:0, 18:0 18:2, 20:4, 22:6 0.1013 46.89%
heart day 28 12170 16:0, 18:0 20:4, 22:6 0.0835 42.57%
heart day 35 49212 16:0, 18:0 20:4, 22:6 0.0799 39.57%
heart 4 mon 24242 16:0, 18:0 20:4, 22:6 0.4948 65.58%
liver 4 mon 5955 16:0, 18:0, 18:1 20:3, 20:4, 20:5, 22:6 0.1832 42.92%
lung 4 mon 32310 16:0, 18:0 18:1, 18:2 0.2506 28.85%
brain 4 mon 4567 16:0, 18:0 18:1, 18:2, 20:3, 22:4 0.7338 28.64%
Table 3.2: Test of quasi-independence on PC molecular species distributions. For each
sample, we identified subsets of sn1 and sn2 fatty acids (FA) for which the subsets passed
the independence test (p≥ 0.05). The % of Total Species indicates the total fraction of PC
made up by species in the independent set for the tissue type.
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Sample
Name
Sample
Size
sn1 FA sn2 FA p-value % of
Total
Species
heart day 1 2178 18:0, 18:1 18:1, 18:2, 20:4, 22:3, 22:4,
22:6
0.1860 43.37%
heart day 7 6461 18:0, 18:1 18:1, 20:0, 20:4, 22:4, 22:6 0.3197 43.23%
heart day 14 4640 18:0, 18:1 18:1, 18:2, 20:0, 20:4, 22:3 0.4231 24.91%
heart day 17 6452 18:0, 18:1 18:2, 20:0, 20:4, 22:4, 22:6 0.0652 46.18%
heart day 21 3471 18:0, 18:1 18:1, 18:2, 20:0, 20:1, 20:4,
22:4, 22:6
0.3723 50.73%
heart day 28 7010 18:0, 18:1 18:1, 22:3, 22:5 0.7417 12.74%
heart day 35 9878 18:0, 18:1 18:2, 20:0, 20:1, 20:4, 22:4,
22:6
0.0517 52.39%
heart 4 mon 7204 16:0, 18:0 20:4, 22:4, 22:5 0.1326 14.27%
liver 4 mon 28197 16:0, 16:1 18:2, 20:4 0.3516 12.08%
lung 4 mon 26989 16:0, 18:1 18:1, 18:2, 20:4, 22:4, 22:6 0.0545 45.34%
brain 4 mon 26242 18:0, 18:1 20:4, 22:5 0.4927 26.14%
Table 3.3: Test of quasi-independence on PE molecular species distributions. For each
sample, we identified subsets of sn1 and sn2 fatty acids (FA) for which the subsets passed
the independence test (p≥ 0.05). The % of Total Species indicates the total fraction of PE
made up by species in the independent set for the tissue type.
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For example, in mature heart data, the sn1 fatty acids {16:0,18:0} and sn2 fatty acids
{20:4,22:6} meet the independence test, and these species contribute 65.58% of the to-
tal PC concentration. Therefore processes controlling species composition in this tissue
appear to be a mixture of position-independent and cooperative mechanisms with indepen-
dence being the more common behavior. This analysis confirms the findings in the previous
section that chains with similar biochemical properties (length and saturation) have a simi-
lar effect on the acyl chain remodeling of other chains in the molecule. For PC, the shorter
saturated chains 16:0 and 18:0 often group at the sn1 position, and the longer unsaturated
chains 20:4 and 22:6 frequently group at the sn2 position.
3.3.4 Trends in processes controlling species composition
The divergence of the observed species distribution from the predicted independent distri-
bution provides a useful quantification of how independent the sn1 and sn2 positions are. I
used Jensen-Shannon Divergence to quantify the difference between two distributions (see
Methods). Figure 3.9 shows the JSD of the observed joint distribution when compared to
the independent distribution for PC and PE and for each sample. Lung PE has the lowest
JSD (0.0268), indicating strong independence of the processes controlling species com-
position at the sn1 and sn2 positions. Liver PE has the highest JSD (0.1851), indicating
greater cooperativity.
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Figure 3.9: Deviation from independence, as a function of tissue type. The overall
deviation of the joint distribution from the expected independent distribution was scored
using JSD for PC (A) and PE (B). The lowest JSD was observed in lung PE (0.0268), while
the highest was observed in liver PE (0.1851). During heart development from day 7 to day
35, a trend of decreasing JSD was observed in PC (R2 = 0.9562, β =−0.0028), while PE
displayed stable JSD during the time period, (R2 = 0.1966, β =−9×10−5).
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I also observed systematic trends in species composition. During heart development,
PC JSD decreases from days 7 to 35 (linear fit: R2 = 0.9562, β =−0.0028). This indicates
that processes that act on the sn1 and sn2 positions independently become increasingly
important over time. However, there is no systematic change in PE JSD during development
(linear fit: R2 = 0.1966, β =−9×10−5). During heart development, PE JSD is lower than
PC JSD at every time point, though mature heart PE JSD is slightly larger than that of
PC JSD. PE is also more independent in mature brain and lung, though PE appears to be
subject to unusually extensive sn1 and sn2 cooperativity in liver.
3.3.5 Comparing complexity of sn1 and sn2 acyl chain remodeling
Which sn position is controlled by more complex regulation? We hypothesized that if
the regulatory mechanisms on one position are more complex, the acyl chain distribution
at that position should display greater variation across conditions. This is analogous to
how the expression of highly regulated genes varies widely across conditions while the
expression of housekeeping genes is constitutive. For instance, if there is greater temporal
regulation of acyltransferase/transacylase activity at one position, one would expect to see
more variability in the distribution of acyl chains at that position through time. Similarly,
if anatomy-specific regulation is greater at one of the positions, the distribution of the acyl
chains at that position should show more variability across tissues. On the other hand,
if the regulation scheme is simpler at one position, then we expect to see a more stable
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acyl chain distribution across conditions. We calculated and compared the variation in sn1
and sn2 marginal distributions across conditions using a multi-distribution Jensen-Shannon
Divergence (higher JSD corresponds to more variation).
Figure 3.10 shows the JSD for marginal distributions during heart development. The
sn1 position exhibits less variation than the sn2 in PE (blue). This is also the case for PC.
Similarly, the JSD of the marginal probabilities across different anatomies (mature heart,
brain, lung, and liver) indicates a higher variability of the sn2 position than in the sn1
position for both PC and PE. According to the above hypothesis, these data indicate that
sn2 positions are subject to more complex regulation than the sn1. Interestingly, the PE JSD
values at the sn2 position are noticeably lower than the PC JSD values at the sn2 position
(PC sn2 has the highest JSD). This is consistent with the prior observation that PC exhibits
stronger sn1-sn2 cooperativity than PE. Stronger cooperative effects allow for finely tuned
regulation of PC species distributions. However, the weaker sn1-sn2 cooperativity in PE is
likely to be less functionally important, since PE species distributions do not appear to be
as regulated.
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Figure 3.10: Comparing complexity of sn1 and sn2 acyl chain remodeling. For each
of PC sn1, PE sn1, PC sn2, PE sn2, the variation of their marginal distributions across
conditions was quantified using a multi-distribution JSD. The sample conditions in (A) are
heart development time points: day 1, 7, 14, 17, 21, 28, 35. The sample conditions in (B)
are four different anatomies: mature heart, brain, lung, and liver. We found that the sn2
position varies more than sn1, suggesting sn2 positions are more subject to regulation than
sn1. This conclusion is consistent for each of PC and PE for both temporal variation and
anatomical variation.
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3.3.6 Identification of species causing deviations from the indepen-
dence model
I performed the following enrichment analysis to test whether the the species that deviate
from independence are consistent across samples. Note that the acyl chain ratios used in
assigning the regioisomes are specific to the tissue type, but identical across time points.
Hence, to avoid bias in the enrichment analysis only mature tissue types are considered.
To determine the species subject to cooperative effects, I calculated standardized resid-
ual scores (see Methods). Out of the 394 summed species in all mature mouse tissues, the
39 (10%) with largest absolute deviations were selected, summarized in Table 3.5. All of
them have positive deviations, indicating that the cooperative effects may be largely due to
synthesis and remodeling rather than degradation. I refer to these 39 species as “deviated
species.”
Given a species S, I investigated its statistical significance and consistency of deviation
across tissue types. I considered a null model where the deviated species are selected at
random from the summed sets of species in all tissues. This null tests the hypothesis that
a species probability of being deviated is independent of its particular acyl chains and the
tissue type. Under this null hypothesis, the number of times I expect to see a species S
as deviated follows the hypergeometric distribution. The statistical significance p-value
of species S drawn at least x times randomly, under the hypergeometric distributions was
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calculated as:
p =
N
∑
i=x
(K
i
)(M−K
N−i
)(M
N
) (3.7)
where M=394 is the total number of observed species summed across all tissue sets;
N=39 is the total number of deviated species; and K is the number of tissue types in which
species S was found (though not necessarily as a deviated species). See scheme in Table 3.4.
At significance level 0.05, I identified 6 species consistently deviating from independence
across tissue types, designated by * in Table 3.5, with p-value given in parentheses.
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heart PC brain PC · · · heart PE brain PE · · · K
Species
16:0-18:2 3.8095 0.7680 · · · -4.4039 n/a · · · 7
16:0-20:4 -0.2603 -3.9704 · · · -9.7514 -15.9078 · · · 8
16:2-20:2 66.5453a 6.5804 · · · n/a 160.6867a · · · 3
18:0-20:4 2.5185 9.2460 · · · -3.1059 0.7850 · · · 8
20:0-16:1 141.5733a n/a · · · n/a n/a · · · 2
20:5-18:0 155.1780a n/a · · · 56.4664a 132.8561a · · · 3
...
Table 3.4: Scheme for the analysis of deviated species across tissues. a indicates devi-
ated species; K is the number of samples in which the species was measured.
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Species Sample Std. Residual
14:0-16:0 lung PC 49.7703
14:0-22:1 liver PC 67.9555
14:0-22:2 heart PE 84.8698
14:1-22:1 heart PC 153.8916
16:0-22:6 liver PE 51.3924
16:2-20:2 * (0.0269) heart PC 66.5453
brain PE 160.6867
16:2-22:3 brain PC 56.2012
18:2-20:2 lung PC 46.0656
18:3-18:0 * (0.0096) liver PC 52.294
liver PE 114.8169
18:3-20:2 brain PC 50.8728
18:3-22:2 heart PC 79.2466
20:0-16:1 * (0.0096) heart PC 141.5733
liver PE 124.0923
20:0-20:5 brain PE 153.9105
20:1-16:0 brain PE 49.7449
20:1-18:3 liver PE 43.8106
20:1-20:5 lung PC 60.9589
20:2-14:1 brain PC 45.8118
20:3-16:0 heart PE 57.9983
20:3-20:0 brain PE 161.9745
20:3-20:2 liver PE 54.2487
20:4-16:0 liver PE 72.1205
20:4-20:1 brain PE 120.3832
20:5-18:0 * (9.03e-04) heart PC 155.178
heart PE 56.4664
brain PE 132.8561
22:1-14:0 * (0.0096) heart PC 149.1648
liver PC 77.1567
22:2-16:2 heart PC 154.6517
22:3-16:0 brain PE 125.8968
22:4-16:0 brain PE 69.2278
22:4-18:0 heart PE 52.088
22:5-14:1 brain PE 161.6675
22:5-16:0 liver PE 101.6345
22:5-18:0 liver PE 83.727
22:6-18:1 * (0.0096) brain PE 70.071
liver PE 120.9603
Table 3.5: Deviated species.
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3.4 Discussion
Using novel statistical approaches, we have identified the major dependence relationships
between sn1 and sn2 acyl chains in PC and PE, the two most common phospholipids in eu-
karyotic membranes. While the mechanisms which determine acyl distributions (synthesis,
degradation, and acyl chain remodeling) generally do not yield sn1-sn2 cooperativity, their
effects are clearly position-specific. This behavior is different from the tetra-acyl phospho-
lipid cardiolipin (CL). For CL, it was shown that the tetra-acyl distributions in most tissues
were well-fit by a model in which the four positional acyl distributions were identical and
lacked cooperativity, and that a model that allowed distinct behavior between sn1 and sn2
positions did not fit the data better. PC and PE are notably different from CL for their strong
distinction in sn1 and sn2 behavior.
Cooperative effects between sn1 and sn2 acyl chains are more apparent for low abun-
dance species, while canonical chains with high abundance generally exhibit independence
between sn1 and sn2 positions. The observed cooperative effects are not due to variation
among the biological replicates, which are taken into account by the Fisher’s test. How-
ever, it should be noted that in the case of minor species, the identification of regioisomers
is sensitive to uncertainties in sn1 and and sn2 relative carboxylate formation during the
mass spectrometry procedure, which in turn may affect the test of independence.
On the other hand some of the low abundance species consistently deviate from inde-
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pendence model across tissues and they tend to be more abundant than expected from the
independence model. The consistency in the deviation is statistically significant, suggest-
ing that the observed cooperativity might arise from preferential recognition by regulatory
enzymes. If correct, we speculate that the low abundance, cooperatively regulated phos-
pholipid species may provide specialized functions for particular tissues or at a particular
developmental stages, analogous to the manner in which highly regulated gene expression
leads to precise tissue- or timing-specific enzyme production. Such phospholipid compo-
sitional regulation may also influence properties such as signaling scaffolds, membrane
fluidity, and energy metabolism in a tissue- and timing- specific manner. This provides
a mechanism for how lipid regulatory enzymes controlling species composition may play
key roles in individualized biological functions.
The enzymes responsible for these cooperative effects remain an important area for
further study. In mammalian cells, it is known that PC is synthesized predominantly via
the CDP-choline pathway, and the PE N-methyltransferase (PEMT) pathway accounts for
30% of synthesis in liver and a smaller fraction in other tissues [22, 23]. In liver, PC
species with mono- or di-unsaturated sn2 acyl groups such as 16:0-18:1/16:0-18:2 are
preferentially created in the CDP-choline pathway [22]. Similarly in heart, PC species
with mono-unsaturated acyl groups at their sn2 position are preferentially synthesized, re-
gardless of the chain type at the sn1 position (e.g., 18:0-18:1/18:1-18:1/16:0-18:1) [24].
Meanwhile, the PEMT pathway shows no substrate specificity for PE, phosphatidyl-N-
monomethylethanolamine, or phosphatidyl-N,N-dimethylethanolamine [25], although mod-
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est specificity for 16:0-22:6/18:0-22:6 has been reported [22]. In our data, we did not ob-
serve a preferential enrichment of 16:0-22:6/18:0-22:6 in liver PC or a depletion in liver
PE. This suggests that in our liver samples the PC acyl chain remodeling processes have
overwritten the distributions created during PEMT synthesis.
The biosynthesis of PE involves the CDP-ethanolamine (Kennedy) pathway and the de-
carboxylation of phosphatidylserine (PS) [26, 27]. These two alternative routes contribute
differently to overall PE synthesis in different tissues. For example, in liver and heart,
the CDP-ethanolamine pathway was reported to produce the majority of PE, whereas in
many other types of cells PS decarboxylase makes > 80% of PE [28, 29]. It has also been
shown that these two pathways generate different PE molecular species [30]. The CDP-
ethanolamine pathway preferentially synthesizes PE species with mono- or di-unsaturated
fatty acids at sn2 position, (e.g., 16:0-18:2/18:1-18:2). The PS decarboxylation pathway
preferentially generates PE species with polyunsaturated fatty acids at sn2 position such as
18:0-20:4 [30]. We did observe slight enrichment of both PE 18:1-18:2 and 18:0-20:4 in
liver, implying modest dependencies between the fatty acids in sn1 and sn2 positions in PE
synthesis.
After de novo synthesis, PC and PE acyl chain remodeling involves transacylation or
deacylation by PLA2 or PLA1, followed by reacylation mediated by various acyltrans-
ferases. Although acyl chain remodeling behaviors have been investigated primarily for
only one sn position at a time, cooperative effects have not been extensively observed
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[31, 32, 33]. This fact supports a quasi-independence model, i.e. sn1 and sn2 positions
are independent for canonical high abundance species, with cooperative effects important
primarily for low abundance species. A more subtle possibility is that there may be coop-
erative effects for high abundance species, but that all high abundance species are subject
to the same effects. A study by Kazachkov et al supports this idea, as they observed that
the activity of the sn2 acyl transferase LPCAT3 was influenced by the chain at the sn1
position, but all saturated sn1 chains (which are more abundant) yielded higher activity
than unsaturated sn1 chains [102]. What controls the abundance of noncanonical species
in membranes is an important question for further study. In addition to acyl transfer and
transacylation, direct chemical modifications and transport may also play a role [103].
This method can set the stage for elucidating the processes controlling lipid species
composition using large-scale lipidomic measurements. Of particular interest are pulse-
chase timecourse experiments that provide measurements of metabolism of heavy-isotope
labeled glycerophospholipid species [104, 17]. These approaches provide highly detailed
information on remodeling of exogenously added glycerophospholipids. While prior stud-
ies have shown qualitatively that remodeling rates at the sn1 and sn2 positions depend on
the saturation states of the chains at the two positions [104], accurate determination of the
network of acyl chain flux and inference of the acyl chain remodeling processes from these
comprehensive and complex datasets are challenging tasks.
The results I have presented here indicate that sn1/sn2 independence can be assumed for
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most high abundance chains, with deviations only for minor species. This finding suggests
that the complexity of the dynamical system that governs phospholipid remodeling can be
substantially simplified from one in which there are frequent sn1-sn2 dependencies. This
will significantly reduce the number of parameters to be inferred. Since the rate parameters
of these reactions are unknown a priori, reduction of the complexity is an important step in
computational inference of the remodeling processes.
This method also suggests it will be feasible to analyze the essential acyl chain re-
modeling behaviors in other acyl-containing phospholipids, such as phosphatidylglycerol
(PG), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), and acyl-
containing glycerolipids such as triacylglycerol (TAG) and compare them in different biomem-
branes. Integrating these species together into a lipid synthesis and acyl chain remodeling
network will be an important challenge. There is a growing requirement to develop further
bioinformatics tools for the analysis of high throughput mass spectrometry lipidomic data
[1]. Statistical models for such data will be vital for elucidating disease mechanisms that
act via the lipidome.
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3.5 Evaluation of the uncertainties in identification of re-
gioisomers
Regioisomers are isomeric lipid species with identical chain types but at different sn posi-
tions (e.g., 18:0-18:2 diacyl PE and 18:2-18:0 diacyl PE). The regioisomer ratio is assessed
by the ratio of the intensities of the paired acyl carboxylates. The ratio of sn1 and sn2 acyl
carboxylates in each lipid class or subclass is pre-determined by extensive examination of
numerous product ion spectra of synthetic lipid standards with known sn1 and sn2 acyl
chain composition. The ratios of sn2 to sn1 acyl carboxylates range from 2.27 to 3.77 and
center at 2.94±0.4 for molecular species in diacyl PE class (See Figure 3.2).
The regioisomer assignment was performed as follows. Let λ denote the synthetic PE
sn2/sn1 ratio and let λmin = 2.27, λmax = 3.77, and λavg = 2.94 denote the min, max, and
the average of the λ values respectively. Let α −β , β −α be an observed regioisomeric
species (e.g., 18:0-18:2 diacyl PE and 18:2-18:0 diacyl PE in 6 month old mouse heart) and
let µ =
[β ]
[α]
be the ratio of the measured concentrations of the fatty acids α and β in the
regioisomers. Then,
[β ] = λ [α−β ]+ [β −α]
[α] = [α−β ]+λ [β −α]
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On the other hand, since the (normalized) concentration of the regioisomers sum to 1, we
get
[α−β ] = −(1−µλ )
(λ −µ)− (1−µλ )
[β −α] = (λ −µ)
(λ −µ)− (1−µλ )
Note that in the above equations, if λ < µ we get that [α−β ]> 1 and [β −α]< 0. Hence
we need to correct the above equation by applying the additional constraint that for λ < µ ,
we set [α−β ] = 1 and [β −α] = 0, i.e., only one isomer will be assigned. This will also
be the case for λ = µ . Figure 3.11 shows the [α−β ] surface.
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Figure 3.11: Concentration of the [α,β ] isomer. For a fixed observed µ value, the con-
centration of the [α,β ] decreases with increasing values of λ .
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As can be seen, the concentration of each regioisomer depends on the choice of λ .
However, the λ dependence on regioisomer concentrations is rather weak in the regime
λ ∈ [2.27,3.77], the range of λ values observed experimentally. In the analysis performed
in this work, λ was set 3 (roughly the mean value) for all the samples.
To see how the choice of λ affects the subsequent statistical analysis, we first re-
performed the clustering analysis on PE data for 6 month old mouse heart for λ = λavg,
λ = λmin, λ = λmin. The experimentally observed ratios of fatty acid chains from carboxy-
late ions are shown in Table 3.6. Figure 3.12 shows the result of the clustering analysis for
different values of λ . The left column shows the conditional chain distributions given the
sn1 chain type. As can be seen the effect of λ on the clustered chain types is minimal for
λmin, λ = λavg, and λ = λmax. Here the only noticeable effect is that 22:5 and 20:4 are not
observed at the sn1 position for the λmin case, but these species are rare at the sn1 position
in all three cases, as can be seen in the right column. Similarly, in the right column the only
notable differences occur when the the sn2 chain is 16:0, 18:1, or 22:5. But these chains
are all rare at the sn2 position.
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Species Isobaric Ratio Content (nmol/mg protein) Acyl Chain Ratio
16:0-18:2/16:1-18:1 10:1 0.19 2.70/1.60
16:0-18:1 0.10 1.20
16:1-20:4 0.07 1.85
16:0-20:4/18:2-18:2 5:1 0.34 4.00/ 1
18:1-18:2 0.22 3.90
18:0-18:2/18:1-18:1 10:1 0.82 6.20/1
18:0-18:1 0.26 3.00
18:0-18:0 0.88 1
16:1-22:6 0.30 5.70
16:0-22:6 7.59 3.37
18:1-20:4 1.23 3.90
18:0-20:4 4.40 2.83
18:2-22:6 1.32 2.89
18:1-22:6 4.79 3.37
18:0-22:6 20.68 1.76
18:0-22:5 1.55 2.29
Table 3.6: Major PE species in 6-mon mouse heart
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Figure 3.12: Clustering of PE for alternative regioisomer assignments. sn1 chain type
clustering (left) and the subsequent sn2 clustering (right) for λ = λmin,λavg, and λmax.
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We next re-performed the test of quasi-independence using the three λ values. As
described above, we selected the sn1 and sn2 chain types for testing based on the clustering
of behaviors shown in Figure 3.11 . The results for the largest set of independent chains
are shown in Table 3.7. For all values of λ , the same set of chain types were found in
this procedure, and these passed the test of quasi independence at the significance level
p ≥ 0.05. Note that the observed set of chains in the sn1 and sn2 positions are similar
to those we had most commonly observed for PE when analyzing the full complement of
tissues Table 3.3. These also tend to be the chain types with high concentrations.
For minor species, the effect of λ may contribute to their apparent deviation from the
independence model. However, some of these species consistently deviate from indepen-
dence in one direction across multiple samples. Hence, it is possible that their observed
deviations are due to systematic biological effects, such as preferential recognition by reg-
ulatory enzymes. For major species the effect of λ on assignment of regioisomer is negli-
gible and does not affect the test of independence.
127
λ Sample Size sn1 FA sn2 FA p-value
λmin = 2.27 1000 18:0, 18:1 18:2, 20:4, 22:6 0.5319
λavg = 2.94 1000 18:0, 18:1 18:2, 20:4, 22:6 0.4732
λmax = 3.77 1000 18:0, 18:1 18:2, 20:4, 22:6 0.4645
Table 3.7: Test of quasi-independence on PE molecular species for alternative regioi-
somer assignments. For each λ , we identified subsets of sn1 and sn2 fatty acids (FA)
which passed the independence test (p≥ 0.05).
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Chapter 4
Dynamics of the ethanolamine
glycerophospholipid remodeling
network
4.1 Introduction
Glycerophospholipids are the dominant lipids in mammalian membranes and are comprised
of a glycerol moiety, a polar head group linked via a phosphate to the sn3 position of the
glycerol moiety as well as an acyl chain esterified to the sn1 and the sn2 positions [16].
The hydrocarbon chain in the sn1-position can also be linked to the glycerol moiety via
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an alkyl or alkenyl ether bond to form plasmalogens. Because of these variations as well
as the variation of the length and number of double bonds, glycerophospholipids comprise
a great number of molecular species. The molecular species composition is regulated by
biosynthesis, turnover and acyl chain remodeling (i.e. the Lands’ cycle [105]), mediated by
phospholipases and acyltransferases or transacylases. Distortions of the molecular species
distributions can lead to severe pathophysiological consequences and have been associated
with many diseases such as Barth Syndrome, heart failure, type 2 diabetes, and several
types of cancer. Understanding of these distortions is a crucial problem, for cell and devel-
opmental biology, potential diagnostics and treatments, and nutrition [5].
Traditionally, the acyl remodeling process has been studied by addressing the speci-
ficity of individual enzymes in vitro using a limited number of substrate species [31, 99,
106, 107]. The recent advances in lipidomics suggest that more relevant data could be
obtained using novel data-mining approaches, but it remains a challenge to accurately in-
fer the remodeling processes from the complex datasets. Some aspects of acyl remodeling
have been revealed by using computational approaches. For example, the molecular species
composition of cardiolipin can be closely fit by a model in which the four cardiolipin acyl
chains are remodeled independently and identically [108, 109, 10]. But the picture is in-
complete as the fit breaks down in case of cancerous tissues and may also be distorted by
cell culture conditions [108]. Pulse-chase time course experiments [104, 17] would be su-
perior to static data for determining the remodeling mechanisms and kinetics, but there are
no computational methods to determine remodeling processes from time course data.
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In this chapter, I present a novel predictive model for remodeling network dynamics that
I developed in collaboration with Dr. Norberto Dı´az–Dı´az and Dr. Kourosh Zarringhalam.
I demonstrate the usefulness of this model by analyzing data from pulse-chase experiments
with 6 different exogenous phosphatidylethanolamine precursors, i.e. 14:0-14:0, 14:1-14:1,
18:3-18:3, 18:0-18:1, 18:1-18:1, 18:0-22:6 [104]. The model assumes that (1) sn1 and
sn2 acyl positions are independently remodeled, (2) remodeling reaction rates do not vary
over time and (3) the concentrations of the acyl donors are constant. These assumptions,
which are based on previous findings on acyl remodeling of phosphatidylethanolamine,
phosphatidylcholine and cardiolipin [110, 108, 10], allowed us to construct a model with
a small number of parameters. We have developed a two-step algorithm to automatically
determine and solve for key remodeling parameters. This algorithm consists of a flux anal-
ysis step allowing to construct (and simplify) the remodeling network and a B-spline -based
parameter inference step that optimally solves the ordinary differential equations govern-
ing the system. Remarkably, the individually solved remodeling mechanisms from the six
experiments cross-validate each other thus strongly suggesting that our model accurately
described the behavior of the biological system under study.
I demonstrate a number of important facts about lipid remodeling. First, 18:1 is the
predominant reacylated acyl chain at both sn1 and sn2 positions, consistent with previ-
ous findings [104]. I also show that the dynamic framework can be used to determine the
deacylation and reacylation rates of different types of acyl chains. For example, we see
that unsaturated chains are substituted more rapidly than saturated ones at the sn1 posi-
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tion (14:1>18:3>14:0>18:0) while at the sn2 position saturated chains more quickly turn
over (14:0 > 14:1). These data are consistent with the fact that saturated acyl chains are
predominant in the sn1 position and unsaturated ones in the sn2 position of diacyl glyc-
erophospholipids. This research demonstrates that computational methods provide means
for detailed modeling of glycerophospholipid remodeling by allowing one to determine the
specificity and kinetics of deacylation as well as reacylation. Notably, the present method
can be readily extended to other glycerophospholipid classes and should thus allow one
to obtain a comprehensive picture of the remodeling process, which is essential for lipid
homeostasis in mammalian cells.
4.2 Methods
4.2.1 Network Inference Algorithm
The remodeling pathway of phospholipids can be thought of as a directed weighted graph
G = (V,E) where the nodes represent the lipid species si, 1≤ i≤ n, and the directed edges
ei, j, 1 ≤ i, j ≤ n representing the flux. Here n denotes the total number of species. The
weight of each edge is proportional to the degree of the flux from source species to the tar-
get species. Here we describe a novel algorithm for inferring such a network from MS time
course measurement such as in pulse chase experiments. Let T = {ti}mi=1 be the measure-
ment times, and m is the total number of measurements. At each time point ti all species
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whose concentration levels are decreasing in the next time point, at a significance level pi
as determined by t-test, are identified as possible remodeling sources. By a source we mean
a species that is remodeled into a target species . The significance level pi depends on the
time point and is defined by pi = θti+1−ti . In practice, parameter inferences are relatively
insensitive to the choice of significance level (Table 4.8).
Denote the set of candidate sources at the ith time point byPi. For each α ∈Pi, we
define the neighborhood N(α), to be the set of lipid species β that share exactly one chain
with α . Next we introduce a correlation function that helps to determine whether β ∈N(α)
could be the remodeling product of α . For a lipid species γ , define
sgn([γ]i) = sgn([γ]i+1− [γ]i) (4.1)
where the sgn([γ]i+1− [γ]i) is determined according to the t-test at the significance level pi.
Let
cor(α,β , ti, tm, p,θ) = δ (α,β , ti, tm, p,θ)
×
tm
∑
h=t1
|([α]h+1− [α]h)([β ]h+1− [β ]h) | (4.2)
where δ (α,β , ti, tm, p,θ) is a sign function that is negative if sgn([α]h)× sgn([β ]h)< 0 for
all i ≤ h < m and positive otherwise. This δ function is introduced to capture the inverse
relation between the concentrations of α and β over the entire time interval [ti, tm].
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For each candidate source α , we associate a set E(α) of edges. The set E(α) is ini-
tialized to the empty set. We then cycle through candidate target set N(α), and for each
member β ∈ N(α), we add an edge eβ to E(α) if cor(α,β , ti, tm, p,θ) < 0 or if there ex-
ist a species γ ∈ N(β ) such that cor(α,β + γ, ti, tm, p,θ) < 0. The second correlation is
introduced to account for the possibility that β is remodeled to γ which reduces the con-
centration of β . We select the γ with highest correlation value. Since the concentrations
of species vary in time, some fluxes may only be visible at later time intervals. These new
fluxes may influence the correlations at the earlier time points. For this reason, If no neg-
ative correlation is found in the time interval [ti, tm], the final time point tm is reduced to
the previous time point tm−1 and the whole process is repeated. We do this until an edge is
found or we reach ti+1. These recursions are repeated for the entire source set. Lastly, the
weights of the edges are set to the correlation values.
4.2.2 B-spline algorithm for solving system of boundary value prob-
lems
The remodeling process of PE is a dynamical system that can be modeled by a set of
coupled differential equations. This dynamical system depends on the rates of conversion
of PE species into one another. These rates are not known a priori. Denote these parameters
by the vector α = (α1, · · · ,α`) ∈ R`, where ` denotes the total number of parameters. Let
x ∈ RN represent the vector of PE concentrations. Here N denotes the total number of
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species. The dynamical system describing the PE remodeling is then:
dx
dt
= f(x,α) (4.3)
Given a set of observations {xˆ(ti)}ni=1, there are a number of available numerical ap-
proximations that can be used to approximate the parameters α using the observed time-
course measurements, while simultaneously solving the differential equations [111, 112,
113]. Since the dependence of the vector field on the parameters is linear, we may rewrite
the parameter inference problem as a minimization problem that can be efficiently solved
using Singular Value Decomposition, SVD, or QR decomposition as described in [114]. We
write the solution u(t) of the above system as a linear combination of cubic B-splines,
u(t)≈ x(t) (4.4)
u(t) =
p
∑
j=0
b jB j(t) (4.5)
where B j(t) are the B-splines and b j ∈RN are the spline coefficients [115, 116]. Define
the error function ED(b) as the square of the distance of the solution u(t) to the observation
points as follows:
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ED(b,α) =
n
∑
i=1
∣∣∣∣∣
∣∣∣∣∣ p∑j=0 b jB j(ti)− xˆ(ti)
∣∣∣∣∣
∣∣∣∣∣
2
(4.6)
Our goal is to minimize the above error function, while simultaneously ensuring that
the solution satisfies the differential equations. The constraint that u has to satisfy the
differential equations second constraint can also be stated in terms of a minimization prob-
lem. More precisely, if we have estimates uˆ(rk) of the solution at the so called “collocation
points”, rk, we can define the error function
EM(b, uˆ) =
q
∑
k=1
∣∣∣∣∣
∣∣∣∣∣ p∑j=0 b j dB j(rk)dt − f(uˆ(rk),α)
∣∣∣∣∣
∣∣∣∣∣
2
(4.7)
which yields the overall error function
E(b,α, uˆ) = λED(b,α)+EM(b, uˆ) (4.8)
where λ is a weight parameter that controls the weight given to the observations versus
the differential equations. Note that the since the dependence of f on α is linear, E is linear
in (b,α). This minimization problem is then readily solved using SVD or QR decompo-
sition. In practice, the approximations uˆ(m) are fitted in an iterative manner where at the
mth step, E is minimized with respect to (b,α) and the resulting b is used to generate the
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new estimate uˆ(m+1). The initial estimate uˆ(0) is set to the solution of the minimization
of Equation 4.6. In our calculations the λ parameter was set to 100. 5 B-splines were
used for initial shooting. 21 B-splines and 49 ((tend− tstart)∗2+1) collocation points were
used for precise approximation to the real function. We iterated for at least 1000 steps
and then stopped at the solution which gives the minimum error among the last 6 steps, to
correct for periodicity issues. The algorithm also stops when the error changes too slowly,
i.e. < 0.0001 between two subsequent steps. Some parameters exhibited periodicity in
the convergence process, which may be related to the shape of the solution space. In such
situations, we only tracked the solution set which gives the lowest error.
As an additional verification, the inferred parameters were used to independently solve
the differential equation using standard numerical techniques. In our implementation we
used the matlab function ode45 with stepsize 0.01 with initial conditions and remodeling
rates as solved by the dynamic algorithm.
4.2.3 Calculate relative Deacylation and Reacylation Rates
Deacylation and reacylation rates were calculated from the k values given in Table 4.2. Note
that in Table 4.2 the conversion rates 14:0->18:1 and 14:0->18:0 have a ratio of 1:0.19,
which is relatively similar to the ratio of the rates 14:1->18:1 and 14:1->18:0 (1:0.18)
and the ratio of 18:3->18:1 and 18:3->18:0 (1:0.26), Table 4.3. This indicates that new
acyl chains are added onto lysophospholipids by a similar process in all experiments, i.e.
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that the pool of available acyl chains is similar. Therefore absolute conversion rates must
differ because of differences in deacylation rates. Based on this logic, relative deacylation
rates can be determined from the ratio of values between rows, while relative reacylation
rates can be determined from the ratios of values between columns. For each comparison,
deacylation and reacylation rate ratios were calculated via an average using the rates found
to exist in the inferred network.
The relative ratios between rows and columns can be formally shown to indicate relative
deacylation and reacylation rates by consideration of the the kinetics of all species and
deacylated intermediates using the steady state approximation for the intermediates. This
approximation is justified by the fact that fully acylated PE is more prevalent than lyso-
species in typical cells. Since the sn1 and sn2 positions are generally independent, we
can consider the behavior of the sn1 (or sn2) position alone. For each chain type xi at the
sn1 position, the kinetics of xi are given by d[xi]/dt = −k(i)− [xi] + k(i)+ [I], where k(i)− is the
deacylation rate of xi, k
(i)
+ is the reacylation rate of xi and [I] is the concentration of the
deacylated intermediate. Assuming that all deacylations lead to the intermediate I and that
d[I]/dt = 0, straightforward algebra shows that the rate parameter in Table 4.2 from initial
chain i to new chain j is k( j)+ k
(i)
− /∑i k
(i)
+ . From this it follows that the ratios of rows and
columns indicate relative deacylation and reacylation rates.
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4.3 Results
We analyzed a set of 6 separate pulse-chase experiments carried out previously [104]. In
those experiments exogenous PE species with a deuterium-labeled head group were intro-
duced to BHK21 cells for 1 hour using a cyclodextrin carrier and the cells were then chased
for 24 h. During the chase, a number of new PE species were generated due to extensive
acyl remodeling as revealed by ESI-MS analysis. The exogenous PE precursors studied
were 14:0-14:0, 14:1-14:1, 18:3-18:3, 18:0-22:6, 18:0-18:1 and 18:1-18:1.
4.3.1 Construct flux network using pulse-chase time course experi-
ments lipidomic data.
We consider the PE remodeling system as a chemical reaction network, defined by a finite
directed graph G= (V,E), where V is the set of vertices consisting of PE molecular species
S = {S1,S2, · · · ,Sn} and E is the set of edges, each representing a remodeling reaction
converting source species to target species. Each edge associates with a remodeling reac-
tion rate that depends on the remodeled chain only. Here we use the sn1 and sn2 position
independence assumption [110] so that any two connected PE species differ at only one
position. Figure 4.1(A) shows the full remodeling network for the 18:3-18:3 PE precursor.
There can be up to n1n2(n1+n2−2) edges in the full network where n1 and n2 represent the
number of sn1 and sn2 chain types, though in practice we do not count edges to PE species
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that are not experimentally observed as part of the full network. Parameter inference on the
full network of interactions would be very slow and is likely to lead to over-fitting.
The remodeling is likely to proceed through a subset of the possible edges in the full
network. The first step toward the identification of the dominant remodeling pathways was
taken in ref. [104], where the unimportant edges in the full network were eliminated by
manually examining the changes in time of the PE species concentrations. Here, we extend
and automate this process using a fast and accurate flux network algorithm that reduces
the complexity of the full network while capturing the dominant chemical reactions, a vital
pre-processing step toward the deciphering of the remodeling system. Briefly, the algorithm
iteratively cycles through candidate "source" and "target" species and examines whether the
concentration of the source species is inversely correlated to the sum of the concentrations
of the target species. The correlation function is designed to capture the inverse relation
between the concentrations and takes the variation in the measurements into consideration
via a user-defined significance level. The significance of each connection is determined
by the value of the correlation function (see Methods for details). Figure 4.1(B) shows
the output of the algorithm for the 18:3-18:3 precursor experiment using significance level
p = 0.3 along with correlation score and the evidence time interval. We observed that
results are relatively insensitive to the choice of significance level (Table 4.8). Figure 4.1(C)
shows the reduced bi-directional flux network that will later be used to construct the set of
ODEs that govern the system. As can be seen, a large component of the flux involves
the conversion of 18:3-18:3 to 18:1-18:3 and the conversion of the latter to 18:1-18:1.
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This suggests that remodeling of 18:3 at the sn1 position is faster than at the sn2 position.
This is consistent with the major path in the 14:1-14:1 experiment, in which the 14:1-14:1
precursor is first converted to 18:1-14:1 and then to 18:1-18:1. However, the major path of
the 14:0-14:0 experiment differs from the previous two experiments, where the precursor
species is first converted to 14:0-18:1 and then to 18:1-18:1, suggesting that remodeling of
14:0 occurs at the sn2 position before the sn1 position. An interesting question is whether
the remodeling mechanisms are still the same in these experiments, and how the apparent
differences in behavior can be explained.
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Figure 4.1: Full PE remodeling network and reduced network based on flux analy-
sis. The full PE remodeling network of 18:3-18:3 pulse-chase experiment consists of all
possible acyl chain exchange reactions between lipid species at any time t, assuming sn1
and sn2 positions are independently remodeled (A). The simpler remodeling network (C)
inferred from flux analysis (B) can be adequate for fast and accurate determination of the
system. Flux analysis identified reactions with significant evidence that one species con-
verts to the other. A large portion of flux in (B) involves 18:3-18:3 converted to 18:1-18:3
and then converted to 18:1-18:1, according to the edge correlation score (Equation 4.2) and
evidence time range in brackets.
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Figure 4.2: Reduced flux network for different precursor experiments, 14:0-14:0 (a),
14:1-14:1 (b), 18:-18:3 (c), 18:0-18:1 (d), 18:0-22:6 (e) and 18:1-18:1 (f).
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4.3.2 Dynamic simulation of ethanolamine glycerophospholipid remod-
eling system.
A set of Ordinary Differential Equations (ODEs) was developed using the inferred reduced
bi-directional flux network for each of the experiments. Table 4.1 shows the dynamical sys-
tem governing the 18:3-18:3 experiment reactions (see Figure 4.1(C) for a graph of the bi-
directional flux network). To infer the model parameters, we implemented an expectation-
maximization-like BSpline algorithm where parameter values are updated iteratively to
minimize an objective error function [114]. The error function is designed to minimize the
distance of the solution to the observed concentrations, subject to the constraint that the
solution satisfies the ODEs that govern the system (See Methods). Figure 4.3 shows the
simulation results for all six experiments. As can be seen, the simulation curves closely
fit the experimental data, suggesting that the models accurately describe the PE remodel-
ing system. The parameter values generally converge rapidly within 1000 iterations (See
Figure 4.4 and 4.5). We also repeated the inference procedure on nonsense data generated
by permuting labels on the PE species. For the label-permuted data, we saw that fits were
either much worse (Figure 4.6) or that the inferred parameters displayed much larger vari-
ation across iterations (Figure 4.7), indicating that the close fits for the real data were not
due to over-fitting. Note that bi-directional constraint is important for successful solving
the system. The model with only one directional reaction failed to fit the experimental data,
see Figure 4.8.
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Production from other species Conversion to other species
d[18:3-18:3]
dt = k6[18:0-18:3]+ k7[18:1-18:3]+ k8[16:1-18:3] −k2[18:3-18:3]− k3[18:3-18:3]− k4[18:3-18:3]
d[16:1-18:1]
dt = k1[16:1-18:3] −k5[16:1-18:1]
d[16:1-18:3]
dt = k2[18:3-18:3]+ k5[16:1-18:1] −k1[16:1-18:3]− k8[16:1-18:3]
d[18:0-18:1]
dt = 0
d[18:1-18:1]
dt = k1[18:1-18:3] −k5[18:1-18:1]
d[18:0-18:3]
dt = k4[18:3-18:3] −k6[18:0-18:3]
d[18:1-18:3]
dt = k3[18:3-18 :3]+ k5[18:1-18:1] −k1[18:1-18:3]− k7[18:1-18:3]
Table 4.1: Differential equation model for PE dynamic remodeling. Shown are the
ODEs for the 18:3-18:3 remodeling system, according to the flux network in Figure 4.1(C).
The reaction parameters k are unknown a priori, and depend on the sn1/sn2 position, initial
chain type, and product chain type. k1 refers to sn2 18:3 to 18:1, k2 refers to sn1 18:3 to
16:1, k3 refers to sn1 18:3 to 18:1, k4 refers to sn1 18:3 to 18:0, k5 refers to sn2 18:1 to
18:3, k6 refers to sn1 18:0 to 18:3, k7 refers to sn1 18:1 to 18:3, k8 refers to sn1 16:1 to
18:3.
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Figure 4.3: Fit of dynamic simulations for six pulse-chase experiments with differ-
ent precursors. 14:0-14:0 (a), 14:1-14:1 (b), 18:3-18:3 (c), 18:0-22:6 (d), 18:0-18:1 (e)
and 18:1-18:1 (f). Simulations (curve) are in good quantitative agreement with measure-
ments (dots and bars indicate mean and standard deviation across replicates). The errors
(Equation 4.8) between prediction and observation are 387, 1064, 2680, 753, 262, and 118
respectively.
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Figure 4.4: Parameter inference error of 14:0-14:0 experiment using B-Spline algo-
rithm. Shown are the error in 1001 iterations, which displayed 4-fold periodicity, shown in
different colors: blue, pink, cyan, gray. This may be related to the shape of solution space.
The blue curve solution gives the closest fit to measurement with lowest error.
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Figure 4.5: Parameter values of 14:0-14:0 experiment using B-Spline algorithm.
Shown are the parameter values in 1001 iterations, which displayed 4-fold periodicity,
shown in different colors: blue, pink, cyan, gray. This may be related to the shape of
solution space. The blue curve solution gives the closest fit to measurement with lowest
error.
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Figure 4.6: Permutation test result. To examine the robustness of the model, we ran-
domly permuted species labels of the data and used them to solve dynamic system defined
by the original data. Shown here are results for the 18:3-18:3 (a) and 14:0-14:0 (b) exper-
iments as examples. As can be seen, the fitting performances are much worse than for the
original data, with larger error 5221 compared to original 2680 (a) and 458 compared to
original 387 (b). The curves are simulations and the dots are randomly permuted data.
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Figure 4.7: Predicted parameter values using randomly permuted 14:0-14:0 data do
not converge.
150
0 5 10 15 20
10
20
30
40
50
60
70
80
90
Chase time (h)
Re
lat
ive
 a
bu
nd
an
ce
 (%
)
 
 18:0/18:1
18:1/18:1
Figure 4.8: Bi-directional reactions are important for accurate solving the system. If
we only model one reaction indicated by flux, 18:0→18:1 as shown here, simulation does
not fit measurement, while adding the other directional reaction with 18:1→18:0 achieved
perfect fit as shown in Figure 4.3E.
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4.3.3 Deacylation and reacylation rates at sn1.
Since the same cell line is used in all experiments, it is reasonable to expect that the inferred
remodeling parameters to be the same, at least for the shared primary conversions, even
though the PE precursors are different in each experiment. To verify this, we compared the
primary effect parameter values across the experiments. The primary effect parameter val-
ues are defined as the remodeling rates connecting the precursor to other chain types. These
rates should be the most accurately inferred due to the initial abundance and large changes
in the precursor concentration over time. As shown in Table 4.2, the sn1 18:0 to 18:1 con-
version rates inferred from the two relevant precursor experiments are highly consistent
(0.0673 and 0.07 in 18:0-22:6 and 18:0-18:1 precursor experiments respectively). Conver-
sion of other sn1 chain types to 18:1 are faster than that of 18:0 in the order 14:1>18:3>14:0
(0.5903, 0.2500, 0.0889), i.e. 14:1 is the most rapidly removed chain while 18:0 is the one
most slowly removed.
To determine whether the reacylation rate depends on the chain being added, we exam-
ined the relative rates of sn1 chain conversion to 18:1, 18:0 and 16:1. For the 14:0-14:0,
14:1-14:1, and 18:3-18:3 PE precursors, the ratios of the conversion rates of the sn1 pre-
cursor to 18:1, 18:0 and 16:1 were 1:0.19:0.29, 1:0.18:(no data), and 1:0.26:0.24, respec-
tively, Table 4.3. Normalization by the precursor to 18:1 rate is necessary to account for
differences in the deacylation rate of the precursors. As can be seen, these ratios show
consistency across experiments. This behavior indicates that a common principle underlies
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the remodeling of the different precursors. Therefore, cross-validation using independent
precursors should be generally effective for determining model robustness. The observed
consistency of rates also indicates that that our method can accurately determine the re-
modeling rates in this system. In general, we were able to distinguish deacylation and
reacylation rates and also determine the relative rates for different chain types using inte-
grative analysis of the combined data (see Methods). For example, the data in Table 4.3
indicate that the sn1 reacylation rates have the order 18:1>16:1>18:0 (1 : 0.27 : 0.21). The
reacylation rates depend on abundance of the given chain type in donor lipid pool and the
selectivity is determined by the acyltransferases/transacylases involved. The deacylation
rates decrease in the order 14:1>18:3>14:0>18:0 (6.58 : 3 : 1 : 0.78), reflecting the speci-
ficity of phospholipase A1, Table 4.4. Thus unsaturated chains are removed faster from
the sn1 position than saturated ones, which are consistent with the fact that saturated chain
types are enriched at sn1. Consistent with our previous suggestion [104], removal 18:1
from the sn1 position is considerably slower than that of other acyl chains such as 14:0 and
18:3.
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new sn1 chain new sn2 chain
Experiment
precursor
Initial
chain
18:1 18:0 16:1 16:0 Initial
chain
18:1 18:2 16:1 20:4
14 : 0−14 : 0 14:0 0.0889 0.0166 0.0261 - 14:0 0.5176 0.1520 - -
14 : 1−14 : 1 14:1 0.5903 0.1083 - - 14:1 0.1400 0.0998 0.1153 0.0769
18 : 3−18 : 3 18:3 0.2500 0.0650 0.0589 - 18:3 0.0555 - - -
18 : 0−22 : 6 18:0 0.0673 - - - 22:6 0.0724 - - 0.1146
18 : 0−18 : 1 18:0 0.0700 - - - 18:1 - - - -
18 : 1−18 : 1 18:1 - 0.0019 0.0072 0.0041 18:1 - 0.0029 - -
Table 4.2: Inferred remodeling rate parameters from six independent experiments. A
“-” indicates unmodeled reactions either due to missing species or low flux in the experi-
ment. The sn1 18:0 to 18:1 rate parameters inferred from two precursor experiments are
similar: 0.0673 and 0.07 for the respective 18:0-18:1 and 18:0-22:6 experiments. The sn1
rate parameters of the first row have ratios 1:0.19:029, similar to ratios in the second row
1:0.18:- and third row 1:0.26:0.24. This indicates that the relative reacylation rates of 18:1,
18:0, and 16:1 are consistently ranked across experiments. Likewise, by comparing values
within a column, we can determine relative deacylation rates, i.e. 14:1 > 18:3 > 14:0 > 18:0
at ratios (6.58 : 3 : 1 : 0.78) at the sn1 position. Analogous behavior was also observed for
the sn2 position.
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Experiment precursor Initial chain type Product chain type
18:1 18:0 16:1
14:0-14:0 14:0 1 0.19 0.29
14:1-14:1 14:1 1 0.18 -
18:3-18:3 18:3 1 0.26 0.24
average 1 0.21 ± 0.04 0.27 ± 0.04
Table 4.3: Estimation of sn1 relative reacylation rates.
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Experiment precursor Initial chain type New chain type
18:1 18:0 16:1 average
14:0-14:0 14:0 1 1 1 1
14:1-14:1 14:1 6.64 6.52 - 6.58 ± 0.08
18:3-18:3 18:3 2.81 3.92 2.26 3.00 ± 0.85
18:0-22:6 18:0 0.76 - -
18:0-18:1 18:0 0.79 - - 0.78
18:1-18:1 18:1 - 0.11 0.28 0.20 ± 0.12
Table 4.4: Estimation of sn1 relative deacylation rates.
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4.3.4 Deacylation and reacylation rates at sn2.
Consistent deacylation and reacylation rates across experiments were also found for the
sn2 position, although there was fewer data than for the sn1 position. For example, the
relative conversion rate of 14:0 to 18:1 vs. 18:2 was 1 : 0.29 (see Table 4.5). This rank
is in agreement with the conversion rates of precursors with 14:1 at the sn2, i.e. 18:1
was preferred to 18:2 in a ratio of 1: 0.71. Based on the integrative analysis described
above, we determined that the deacylation rates of different chain types decrease in the
order 14:0>14:1>22:6>18:3 (2.61 : 1 : 1 : 0.4), Table 4.6. It is interesting to note that the
saturated or monounsaturated chains are removed faster than polyunsaturated ones, thus
providing a possible explanation why the sn2 position is enriched in polyunsaturated acyl
chains. Removal of 18:1 from the sn2 position also appears to be slower than that of 14:0
and 14:1. A unexpected observation is that from 18:0-22:6 PE precursor experiment, the
sn2 22:6 chain converts to 20:4 much faster than to 18:1. This conflicts with the reacylation
rates predicted from the behavior of a 14:1 chain at sn2, which is replaced by 18:1 twice
as fast as by 20:4. This phenomenon is worth further investigation as it may indicate a
cooperative interaction between sn1 and sn2 chain remodeling.
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Experiment precursor Initial chain type Product chain type
18:1 18:2 16:1 20:4
14:0-14:0 14:0 1 0.29 - -
14:1-14:1 14:1 1 0.71 0.82 0.55
18:0-22:6 22:6 1 - - 1.58
average 1 0.5 ± 0.3 0.82 1.07 ± 0.73
Table 4.5: Estimation of sn2 relative reacylation rates.
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Experiment precursor Initial chain type New chain type
18:1 18:2 16:1 20:4 average
14:0-14:0 14:0 3.7 1.52 - - 2.61 ± 1.54
14:1-14:1 14:1 1 1 1 1 1
18:3-18:3 18:3 0.4 - - - 0.4
18:0-22:6 22:6 0.52 - - 1.49 1 ± 0.69
18:1-18:1 18:1 - 0.02 - - 0.02
Table 4.6: Estimation of sn2 relative deacylation rates.
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We also observed consistencies in secondary effect parameters, Table 4.7. For instance,
the sn1 16:1 to 18:1 conversion rate was found to be 0.0395 for the 14:0-14:0 precursor
and 0.0358 in the 18:1-18:1 precursor. On the other hand, the sn2 18:2 to 18:1 conversion
rates were determined to be 0.0388 and 0.0396 with the respective precursors. Since these
inferences are based on lower abundance species not contained in any precursor, they may
be more sensitive to experimental errors. Experiments with precursors having sn1 16:1 or
sn2 18:2 would be beneficial to determine if the model also provides accurate secondary
rate parameters.
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Experiments sn1 parameters sn2 parameters
14 : 0−14 : 0
14:0→ 18:1∗ 0.0889 14:0→ 18:1∗ 0.5176
18:0→ 14:0 0.0652 22:6→ 18:1 0.1669
16:1→ 14:0 0.0638 14:0→ 18:2∗ 0.1520
18:1→ 16:1 0.0561 16:1→ 18:1 0.0808
16:1→ 18:1 0.0395 18:2→ 18:1 0.0388
18:1→ 14:0 0.0354 16:1→ 18:2 0.0100
14:0→ 16:1∗ 0.0261 20:4→ 18:1 0.0005
14:0→ 18:0∗ 0.0166
14 : 1−14 : 1
14:1→ 18:1∗ 0.5903 20:4→ 18:1 0.2832
14:1→ 18:0∗ 0.1083 18:2→ 14:1 0.2744
22:6→ 18:1 0.1564
14:1→ 18:1∗ 0.1400
16:1→ 14:1 0.1337
14:1→ 16:1∗ 0.1153
14:1→ 18:2∗ 0.0998
14:1→ 20:4∗ 0.0769
18:1→ 14:1 0.0458
18:1→ 22:6 0.0067
18 : 3−18 : 3
18:3→ 18:1∗ 0.2500 18:3→ 18:1∗ 0.0555
18:3→ 18:0∗ 0.0650
18:3→ 16:1∗ 0.0589
18 : 0−22 : 6
16:0→ 18:1 0.4093 20:4→ 22:6 0.1253
18:1→ 16:0 0.0869 22:6→ 20:4∗ 0.1146
18:0→ 18:1∗ 0.0673 22:6→ 18:1∗ 0.0724
18:1→ 18:0 0.0067 18:1→ 22:6 0.0036
18 : 0−18 : 1
18:0→ 18:1∗ 0.0700
18:1→ 18:0 0.0346
18 : 1−18 : 1
18:0→ 16:0 0.0373 18:2→ 18:1 0.0396
16:1→ 18:1 0.0358 18:1→ 18:2∗ 0.0029
16:0→ 18:1 0.0338
16:1→ 18:0 0.0283
18:1→ 16:1∗ 0.0072
18:1→ 16:0∗ 0.0041
18:1→ 18:0∗ 0.0019
Table 4.7: Summary of parameter inference results. * indicates primary effect parame-
ters.
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4.4 Discussion
Due to the complexity of lipid remodeling and the lack of previous computational tools,
quantitative analyses are few [1]. In this chapter, I present the first model for inferring
the dynamics of phospholipid remodeling processes and show that it is able to robustly
model the biological phenomenons. The network structure is automatically inferred using
a fast flux analysis step and the kinetic parameters are then determined through an efficient
B-Spline based optimization approach.
To appreciate the importance of such computational modeling, it is useful to compare
the results with those deduced empirically. Figure 4.9 shows the distribution of acyl chains
at the sn1 and sn2 positions of PE at the final time point in each experiment, which is when
the experiments should behave most similar to one another. The distribution of acyl abun-
dances is relatively similar across the experiments (ignoring species with missing data)
with different PE precursors. At the sn1 position, the 16:0 abundance is consistent (all
values 0.12±0.03) for the 14:0-14:0, 14:1-14:1 and 18:0-22:6 precursors. Likewise, the
16:1 abundance is consistent between experiments with 14:0- 14:0, 18:3-18:3, 18:0-22:6
(0.22±0.04) precursors. However, with the 18:1-18:1 precursor the non 18:1 abundances
are systematically less than expected, probably due to "precursor bias". Similarly, the sn1
18:0 values are biased upward for the precursors with 18:0 at sn1. Such precursor biases
obscure the consistency of the remodeling process across experiments when data are ana-
lyzed without a dynamic model. Analogous behavior was found for the sn2 position. We
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also note that in an empirical analysis it is difficult to distinguish whether the remodeling
behavior is affected by interaction between the sn1 and sn2 chains. While the prior empir-
ical analysis suggested a variety of behaviors dependent on the saturation at both the sn1
and sn2 positions [104], the present modeling approach indicates that chains are largely
independently remodeled. In addition, we can quantitatively determine the kinetics, which
is not possible without computational modeling. For example, we are able to determine
that the sn1 deacylation rate varies by an order of magnitude depending on the respective
acyl chain (Table 4.4).
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(a) sn1
(b) sn2
Figure 4.9: PE acyl chain proportion at the final time point after chase.
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Figure 4.9: PE acyl chain proportion at the final time point af-
ter chase. The set of allowed chains at the sn1 and sn2 positions are
i ∈ Ωsn1,Ωsn1 = {14:0,14:1,18:3,16:0,16:1,18:0,18:1} and j ∈ Ωsn2,Ωsn2 =
{14:0,14:1,18:3,16:1,18:1,18:2,20:4,22:6}, which are the collections of observed
chain types among the six experiments. The abundances of chain types at sn1(a) and sn2
(b) were normalized by the predominant reacylated chain type (18:1) to control for the
total amount of reacylation. This normalization allows us to compare newly generated
chain types, distinguish precursor effect and detect missing species. We ignored chain
types that appear to arise only from their experimental precursors. As can be seen, ignoring
species with missing data, the distribution of acyl abundances is relatively similar across
experiments. At the sn1 position, the 16:0 abundance is consistent (all values 0.12±0.03)
for precursors 14:0-14:0, 14:1-14:1, and 18:0-22:6. Likewise, the 16:1 abundance is
consistent between experiments 14:0-14:0, 18:3-18:3, 18:0-22:6 (0.22±0.04). 18:0 is
consistent between experiments 14:0-14:0, 14:1-14:1, and 18:3-18:3 (0.14±0.03) and
between two experiments as precursor 18:0-18:1 and 18:0-22:6 (0.60 and 0.61). However,
non-18:1 abundances for the 18:1-18:1 precursor experiment are systematically depressed,
likely due to bias from the precursor. At the sn2 position, 14:0-14:0 and 14:1-14:1
experiments have consistent proportions of 18:2 (0.086±0.004) and 20:4 (0.14±0.02).
However, there seem to an absence of species containing those chain types in the 18:3-
18:3, 18:0-18:1 and 18:1-18:1 experiments. In fact, in the 18:3-18:3 experiment, labeled
species concentrations only sum up to 76%. We also observed that the sn1 16:1 chain
type is underestimated in the 14:1-14:1 experiment and more abundant at the sn2 position
than that from 14:0-14:0, which may be due to uncertainty in isomer identification.
However, despite these discrepancies, the data largely agree on their remodeled chain type
proportions.
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sn1 sn1 sn1 sn2 sn2
threshold num edges num para error 14:0→18:1 14:0→16:1 14:0→18:0 14:0→18:1 14:0→18:2
0.1 16 14 400 0.0893 0.0312 - 0.6197 -
0.2 26 22 394 0.0911 0.0256 0.0213 0.5260 0.1216
0.3 32 24 387 0.0889 0.0261 0.0166 0.5176 0.1520
0.4 50 38 372 0.0801 0.0269 0.0130 0.3836 0.1062
full 66 50 371 0.0688 0.0242 0.0163 0.3426 0.1018
Table 4.8: The primary parameter values of 14:0-14:0 experiment are relatively in-
sensitive to the choice of significance level.
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This study provides a significant advance as compared to previous lipidomic data min-
ing approaches, which focused on steady-state systems as described in Chapter 2, or were
based on dynamic simulations without an explicit method for parameter inference [10].
These acyl chain remodeling studies complement studies addressing metabolic fluxes be-
tween classes of lipids with different head groups [60, 117]. Even though mass spectrom-
etry measurements used to obtain the raw data have some positional isomer and missing
data uncertainties, it is remarkable that our simulations not only all provide good fits but
also cross validate in the parameter values. This suggests that the model is not excessively
sensitive to measurement uncertainties and thus captures the essential features of the re-
modeling process invivo. A strength of our method is that it is based on the straightforward
position-independence assumption, which has previously found to be valid for the tetra-
acyl phospholipid cardiolipin [108]. The success of the present model indicates sn-position
independence is typical for glycerophospholipid acyl chain remodeling.
In summary, I present a powerful modeling tool for the analysis of glycerophospholipid
remodeling pathways and kinetics. This method will be particularly valuable when com-
bined with knock-down of putative remodeling enzymes or other similar perturbations.
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Chapter 5
Concluding Remarks
5.1 Summary
The regulation and maintenance of the cellular lipidome through biosynthetic, remodel-
ing, and catabolic mechanisms are critical for biological homeostasis during development,
health and disease. These complex mechanisms control the architectures of lipid molecular
species, which have diverse yet highly regulated fatty acid chains at both the sn1 and sn2
positions. Technical advances in lipidomic analysis have generated tremendous amounts of
quantitative lipid molecular species data, providing valuable information for richer under-
standing of the functions of the cellular lipidome.
In this dissertation, I have described novel computational methods to analyze complex
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lipidomic data, focusing on one of the most important classes of lipids, glycerophospho-
lipids.
5.1.1 Mathematical framework to interpret complex lipid species dis-
tributions
First, I have presented a mathematical model describing cardiolipin molecular species
distribution in steady state and its relationship with fatty acid chain compositions. The
mitochondrial-specific lipid cardiolipin (CL), is unique among phospholipids due to its
four acyl chains. The lengths and degree of unsaturation of these acyl chains vary across
CL molecules, and regulation of these differences is important for mitochondrial energy
metabolism. I described a novel mathematical approach to determine mechanisms control-
ling the steady-state distribution of acyl chain combinations in CL .
I analyzed mitochondrial lipids from 18 types of steady-state samples, each with at
least 3 replicates, from mouse brain, heart, lung, liver, tumor cells, and tumors grown in
vitro. Using a mathematical model for the CL remodeling mechanisms and a maximum
likelihood approach to infer parameters, I found that for most samples the four chain po-
sitions have an independent and identical distribution, indicating they are remodeled by
the same processes. Furthermore, for most brain samples and liver, the distribution of acyl
chains is well-fit by a simple linear combination of the pools of acyl chains in phosphatidyl-
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choline (PC), phosphatidylethanolamine (PE), and phosphatidylglycerol (PG). This sug-
gests that headgroup chemistry is the key determinant of acyl donation into CL, with chain
length/saturation less important. This remodeling behavior appears to have changed in
some tumor samples, which display a consistent excess of CL molecules having particular
masses.
For heart and lung, the "proportional incorporation" assumption is not adequate to ex-
plain the CL distribution, suggesting additional acyl CoA-dependent remodeling that is
chain-type specific. These findings indicate that CL remodeling processes can be described
by a small set of quantitative relationships, and that bioinformatic approaches can help de-
termine these processes from high-throughput lipidomic data. Knowledge of this behavior
will facilitate determination of isomeric species for complex lipids, providing more detailed
information beyond current limits of mass spectrometry technology.
5.1.2 A statistical analysis framework for diacyl- glycerophospholipid
In this chapter, I have presented statistical studies of mechanisms influencing phosphatidyl-
choline and phosphatidylethanolamine molecular architectures. Phosphatidylcholine (PC)
and phosphatidylethanolamine (PE) serve as the predominant biophysical scaffolds in mem-
branes, acting as reservoirs for potent lipid signals and regulating numerous enzymatic pro-
cesses. I reported the first rigorous computational dissection of the mechanisms influencing
PC and PE molecular architectures from high-throughput shotgun lipidomic data.
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In PC and PE, sn1 and sn2 positions are largely independent, though for low abundance
species regulatory processes may interact with both the sn1 and sn2 chain simultaneously,
leading to cooperative effects. Chains with similar biochemical properties appear to be re-
modeled similarly. sn2 positions are also more regulated than sn1, and PC exhibits stronger
cooperative effects than PE. A key aspect of this work was a novel statistically rigorous ap-
proach to determine cooperativity based on a modified Fisher’s exact test using Markov
Chain Monte Carlo sampling. This computational approach provides a useful tool for de-
veloping mechanistic insight into lipidomic regulation.
5.1.3 Dynamic simulation of ethanolamine glycerophospholipid remod-
eling
Finally, I presented the novel dynamic network of ethanolamine glycerophospholipid (PE)
remodeling, using data from six independent pulse-chase experiments and a novel bioin-
formatic network inference approach. This study accurately predicts dynamic lipid species
changes in pulse-chase experiments. I developed a novel fast and accurate two-step al-
gorithm to automatically infer model parameters. The dynamic model closely fits experi-
mental measurements and shows strong cross-validation across experiments with distinct
deuterium-labeled precursors. A key outcome is that we were able to robustly determine the
deacylation and reacylation rates of individual acyl chain types at the sn1 and sn2 positions,
and these explain the well-known prevalence of sn1 saturated chains and sn2 unsaturated
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chains. This computational approach demonstrates that dynamic acyl chain remodeling
processes can be robustly and precisely determined from dynamic lipidomic data.
5.2 Future studies
Mass spectrometry technologies have rapidly progressed over the last decade, changing the
scale and resolution of lipid analytical strategies. These platforms are generating unprece-
dented amounts of data, presenting novel statistical and computational challenges.
The Lipid Metabolites and Pathways Strategy (LIPID MAPS) Consortium, funded by
NIGMS, is aiming to comprehensively measure all of the lipids in the macrophage cell
line RAW 264.7. To facilitate sharing of data and interpretation of results, they established
standardized lipid classification system and nomenclatures. It is likely that individual labo-
ratories will soon be conducting large-scale lipidomic studies of their own interest. Further
standardized data formats are an important challenge for lipid bioinformatics.
As more higher resolution lipid species data are generated, high-performance com-
puting technologies, such as general purpose computation on graphics processing units
(GPGPU) and cloud computing, will be critical to handle computationally intensive tasks
and speed up data analysis pipelines. One direction of my future interest is to develop data
mining algorithms that are adaptable to high-performance computing.
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Despite the initial success in identifying individual lipid species, the mass spectrom-
etry technologies are limited in absolute quantifications of isomeric species. This is due
to the nature of mass spectrometry, which alone can only distinguish the total number of
carbons and double bonds of a lipid. The current assignment of acyl chain configurations
are based on approximations from the fragmentation intensities of sn-1 and sn-2 carboxy-
late groups. Moreover, despite existing methodologies, low abundance species are often
ignored in many studies. This causes a problem for downstream analysis, making it is hard
to distinguish biological phenomena from measurement uncertainties or errors. To be more
accurate, it is imperative to use automatic data processing and analysis pipelines. Further
emphasis on examining lipid species quality from the mass spectrometry measurements
will be required. It is a challenge to develop lipid analysis tools able to deal with these
caveats and produce more reliable interpretations.
Lipid molecular species are critical elements necessary for a comprehensive systems
analysis of cellular signaling networks. As accuracy and throughput of mass spectrometry
technologies improve, lipidome-wide studies will undoubtedly be widely used to further
our understanding of human diseases and translate into improved therapies.
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As part of my dissertation work, I have also developed an framework using docking
simulations to assist design for ultrasensitive protein nanosensors, (in collaboration with
Chiles laboratory) [118] and developed a prototype pipeline for genome-wide mutational
profiling using next-generation sequencing technologies (SOLiD) (with Marth laboratory)
[119].
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ABBREVIATIONS
ALCAT1 CoA:lysocardiolipin acyltransferase
B6 C57BL/6J mouse strain
CDP-DAG cytidine diphosphate-diacylglcyerol
CL cardiolipin
CID collision induced dissociation
CT-2A experimental murine anaplastic astrocytoma
EPEN experimental murine ependymoblastoma
ESI/MS electrospray ionization mass spectrometry
FA fatty acid
GC gas chromatography
LC liquid chromatography
iPLA2 calcium-independent phospholipase A2
JSD Jensen-Shannon Divergence
MCMC Markov Chain Monte Carlo
MDMS-SL multi-dimensional mass spectrometry-based shot-
gun lipidomics
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ABBREVIATIONS
MLCL AT monolysocardiolipin acyltransferase
MS/MS tandem mass spectrometry
ODE ordinary differential equation
PA phosphatidic acid
PC phosphatidylcholine
PE phosphatidylethanolamine
PEMT PE N-methyltransferase
PG phosphatidylglycerol
PS phosphatidylserine
PUFA polyunsaturated fatty acids
TAG triacylglycerol
TLC thin layer chromatography
VM VM/dk mouse strain
VM-NM1 spontaneous murine non-metastatic brain tumor
VM-M2 spontaneous murine metastatic brain tumor
VM-M3 spontaneous murine metastatic brain tumor
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